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The comprehensive summery of work incorporated in the thesis with
the title “STUDIES ON SOME COMPOUNDS OF THERAPEUTIC IN-
TEREST ” has been described as under.
[A] STUDIES ON IMIDAZO[1,2-a]PYRIDINES
[B] STUDIES ON DIHYDROPYRIMIDINES
[C] STUDIES ON 1,4-DIHYDROPYRIDINES
[A] STUDIES ON IMIDAZO[1,2-a]PYRIDINES
We are engaged in a programme to explore novel heterocyclic enti-
ties in order to study their pharmacological profile our efforts are focused on
introduction of chemical derivatives in the molecular frame work in order to
synthesizing active molecules of different composition.
Heterocyclic compounds bearing imidazo[1,2-a]pyridine ring system
are endowed with variety of biological activities. Our strategy is based on to
develop new bioactive entities especially with pharmacological activities bear-
ing heterocyclic ring system. Literature survey reveals that nitrogen containing
heterocyclic compounds like imidazo[1,2-a]pyridines have received consider-
able attention in medicinal science due to their biological and pharmacological
activities like anti-inflammatory, herbicidal, hypnotic, sedative, antimicrobial,
antitubercular, CNS depressants and many others.
Considering the increasing importance of [1,2-a] pyridine nucleus
prompted us to design and synthesize some heterocycles with chalcones,
pyrazolines, cyanopyridines, cyclohexenone, schiff’s base, arylaminomethyl,
thiazolidinone, etc bearing imidazo[1,2-a]pyridine nucleus, which have been
described as under.
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PART-I  : STUDIES ON PYRAZOLINES
Among a wide variety of heterocycles that have been explored for
developing biologically active molecules like pyrazolines have played important
role in medicinal chemistry. Pyrazolines have been found to posses bacteri-
cidal, antiviral and other pharmacological properties like anticonvulsant and anti-
inflammatory. These valid observations led us to synthesize some new pyrazoline
derivatives which have been described in following sections.
SECTION-I  : Synthesis and biological screening of 1-Aryl 3-[6-me-
thyl-2-(4-methylphenyl) imidazo [1,2-a] pyridin-3-yl]prop-2-ene-1-ones
                                  
N
N
O
CH3
CH3
R
The chalcones of type (I) have been synthesized by the condensation
of 6-Mehtyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde with
different acetophenones in the presence of 40% Sodium hydroxide.
SECTION-II  : Synthesis and biological screening of 3-(3-Aryl-4,5-
dihydro-1H -pyrazol-5-yl)-6-methyl-2-(4-methylphenyl)imidazo[1,2-
a]pyridines
       Type (I)                R = Aryl
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N
N
NH
N
CH3
CH3
R
Pyrazoline derivatives of type (II) have been synthesized by the
cyclocondensation of the 1-Aryl-3-[6-methyl-2-(4-methylphenyl)imidazo [1,2-
a]pyridin-3-yl]prop-2-ene-1-ones of type (I) with hydrazine hydrate.
 SECTION-III  : Synthesis and biological screening of 3-(3-Aryl-1-phe-
nyl-4,5-dihydro-1H-pyrazol-5-yl)-6-methyl-2-(4-methylphenyl)imidazo
[1,2-a]pyridines
                               
N
N
N
N
CH3
CH3
R
Pyrazoline derivatives of type (III) have been synthesized by the
cyclocondensation of the 1-Aryl-3-[6-methyl-2-(4-methylphenyl)imidazo [1,2-
a]pyridin-3-yl]prop-2-ene-1-ones of type (I) with phenyl hydrazine in metha-
nol.
PART-II : STUDIES ON CYCLOHEXENONES
Cyclohexenone derivatives have drawn considerable attention due to
their good pharmacological activities like antifungal, cardiovascular, sedative,
Type (III)               R = Aryl
    Type (II)                   R=Aryl
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antibacterial, antiviral and other pharmacological properties. By considering
these valid observations, we have synthesized some new cyclohexenone which
have been described as under.
SECTION-I : Synthesis and biological screening of Methyl-4-aryl-6-[6-
methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]cyclohex-2-one-3-
ene-1-carboxylates
                                     
N
N
CH3
CH3
O
R
MeOOC
Cyclohexenones of  type (IV) have been prepared by the
condensation of chalcones of type (I) with methylacetoacetate in the presence
of basic catalyst K2CO3.
SECTION-II : Synthesis and biological screening of Ethyl-4-aryl-6-[6-
methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]cyclohex-2-one-3-
ene-1-carboxylates
                                            
N
N
CH3
CH3
O
R
EtOOC
Type (IV)                        R = Aryl
  Type (V)                         R = Aryl
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Cyclohexenones of type (V) have been prepared by the con-
densation of chalcones of type (I) with ethyl acetoacetate in the presence of
basic catalyst K2CO3.
SECTION-III : Synthesis and biological screening of 1-Acetyl-4-aryl-6-
[6-methyl-2-(4- methylphenyl)imidazo[1,2-a]pyridin-3-yl]cyclohex-2-one-
3-enes
                                    
N
N
CH3
CH3
O
R
MeOC
Cyclohexenones of type (VI) have been prepared by the con-
densation of chalcones of type (I) with acetyl acetone in the presence of basic
catalyst K2CO3.
PART-III  : STUDIES ON CYANOPYRIDINES
Like other heterocyclic compounds, pyridines with different functional
groups exhibit wide range of applications in the field of pharmaceutical and
agriculture. Cyanopyridine derivatives have been reported to be active as anti-
fungal, antidiabetic, anticholestemic, etc. On the basis of these results, we have
synthesized some new derivatives which have been described as under.
SECTION-I  : Synthesis and biological screening of 2-Amino-6-aryl-4-
[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]nicotinonitriles
Type (VI)                        R = Aryl
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N
N
N
NH2
CH3
R
CH3
N
Cyanopyridine derivatives of type (VII) have been prepared by the
reaction of chalcones of type (I) with malononitrile and ammonium acetate.
PART-IV  : STUDIES ON ARYLAMINOMETHYL DERIVATIVES
Arylaminomethyl derivative represents one of the modest classes of
biological active agents which have been deeply studied as new potential agents.
These have been reported to be active as antitubercular, anticancer, insecti-
cidal, etc. In view of these valid observations, we have synthesized some new
arylaminomethyl derivatives which have been described as under.
SECTION-I : Synthesis and biological screening of N-Aryl-1-[6-me-
thyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methanimines
     
N
N
N
CH3
CH3
R
The azomethines of type (VIII) have been prepared by the conden-
sation of 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde
with different aromatic amines using acetic acid as a catalyst.
 Type (VIII)                 R = Aryl
  Type (VII)              R = Aryl
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SECTION-II : Synthesis and biological screening of N -Aryl-1-[6-me-
thyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methanamines
                 
N
N
NH
CH3
CH3
R
The compounds of type (IX) have been synthesized by the reaction
of arylamines of type (VIII) with NaBH4.
    [B] STUDIES ON DIHYDROPYRIMIDINES
The synthesis of dihydropyrimidine derivatives is having important
drug potential because of their pharmacological activities. Many of them are
biologically important since they behave as calcium channel blockers, antihy-
pertensive agents. This observation led us to synthesize some newer di
hydropyrimidinones and dihydropyrimidinethiones derivatives shown as under.
PART-I  : STUDIES ON DIHYDROPYRIMIDINONES
Dihydropyrimidinone and its derivatives have been important task for
the research chemist. They possess biological activities such as significant in
vitro activity against unrelated DNA and RNA virus, antimalarial, diuretic, an-
timicrobial and antineoplastic. That has been explored for developing biologi-
cally active molecules. The above observations created the interest for the syn-
thesis of dihydropyrimidinones which have been described as under.
SECTION-I : Synthesis and biological screening of 4-Aryl-6-isopro-
pyl-5-[N-(3-nitrophenyl) amino carbonyl]-3,4-dihydro pyrimidine-2(1H)-
ones
 Type (IX)                  R = Aryl
008
NO2
NH
N
H
CH3
CH3
NH
R
O
O
Dihydropyrimidinones of type (X) have been synthesized by the con-
densation of 4-Methyl-N-(3-nitrophenyl)-3-oxopentanamide, urea and aryl al-
dehydes in the presence of HCl as a catalyst.
PART-II : STUDIES ON DIHYDROPYRIMIDINETHIONES
Thiopyrimidinone ring system have a prominent feature in medicinal
chemistry and possess biological activities such as analgesic, insecticidal,
antibacterial, antidiabetic, anticonvulsant, etc. In view of these facts, it was
contemplated to synthesize thiopyrimidinone derivatives which have been
described as under.
SECTION-I : Synthesis and biological screening of 4-Aryl-6-isopro-
pyl-5-[N-(3-nitrophenyl)amino carbonyl]-3,4-dihydro pyrimidine-2(1H)-
thiones
                                         
NO2
NH
N
H
S
R
CH3
CH3
NH
O
Type (X)            R = Aryl
Type (XI)          R = Aryl
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Dihydropyrimidinethiones of type (XI) have been synthesized by the
cyclization of  2-Arylidene-4-methyl-N-(3-nitrophenyl)-3-oxopentanamide with
thiourea in presence of potassium bicarbonate.
    [C] STUDIES ON 1,4-DIHYDROPYRIDINES
Recently 1,4-dihydropyridines  have drawn considerable attention due
to their good pharmacological activities like sedative, anticancer, antibacterial,
cardiovascular, etc. By considering  these valid observations, it was contemplated
to synthesize some novel 1,4-dihydropyridines possessing higher biological
activity that have been described as under.
SECTION-I : Synthesis and biological screening of 4-Aryl-2,6-diisopropyl
-3,5-bis[N-(3-nitrophenyl)amino carbonyl]-1,4-dihydro pyridines
  
NO2
N
H
CH3
CH3
NH
O
NH
O
NO2
CH3
CH3
R
1,4-Dihydropyridines of type (XII) have been prepared by the cyclo
condensation of 4-Methyl-N-(3-nitrophenyl)-3-oxopentanamide with aryl al-
dehydes in ammonical methanol.
The constitution of the synthesized compounds has been character-
ized by elemental analyses, IR and 1H NMR spectroscopy and further sup-
ported by MS spectra. Purity of all the compounds have been checked by TLC.
’
Type (XII)                R = Aryl
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 IN VITRO STUDIES ON BIOLOGICAL  ACTIVITIES
All the compounds have been evaluated for their antibacterial ac-
tivities towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg.
The biological activity of the synthesized compounds has been compared with
standard drugs.
        DR. V.  R. SHAH       NAINESH N. KANSAGARA
STUDIES ON
SOME COMPOUNDS OF
THERAPEUTIC INTEREST
                           Introduction...
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INTRODUCTION
The chemistry of therapeutic interested compounds had it’s beginning when
chemists, pharmacists and physicians isolated purified active principles of plant and animal
tissues and later from micro organisms and their fermentation products. Some of these
chemicals had been associated with therapeutic properties is often ill-defined disease
condition.
The current interest in the creation of large, searchable libraries of organic
compounds has captured an imagination of chemists and the drug discovery community.
Efforts in numerous laboratories focused on the introduction of chemical diversity have
been recently reviewed and pharmacologically interesting compounds have been identified
from libraries of widely different composition.
The progress of drug design is extensively driven by the instincts, intuition and
experience of pharmaceutical research scientists. It is often instructive to attempt to
‘capture’ these experiences by analyzing the historical record that is successful drug
design projects to past. From this analysis the interference draw to play an  important
role in shaping our current  and  future projects. Towards this region, we would like to
analyze the structures of a large number of drugs.
The word ‘drug’ is derived from the French word ‘drogue’ which means a dry
herb. According to “WHO” a drug may be defined as “any substance or product which
is used or intended to be used for modifying or exploring physiological   system or
pathological status for the benefit of recipient”.
Drug’s action is believed to be due to the interaction of the drug with enzymes,
receptors and other molecules found in the biological system. The binding of a drug to
the active or other sites of an enzyme usually has the effect of preventing the normal
operation of that enzyme. The stronger the binding of the drug to the enzyme and greater
                           Introduction...
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the number of sites occupied, the more effective the drug is likely to be in inhibiting the
action of the enzyme.
The degree of drug activity is directly related to the concentration of the drug in
the aqueous medium in contact with the active or receptor site. The factors affecting this
concentration in a biological system can be classified in to two phase.
(I) The pharmacokinetic phase
It is concerned with the study of the parameters that control the journey of the
drug from its point of administration to its point of action. It includes the absorption,
distribution, metabolism and elimination of a drug.
(II) The pharmacodynamic phase
It is concerned with the result of the interaction of drug and body at the receptor
site, that is, what the drug does to the body. This includes physiological  and  b ioche
mical effects of drugs and their mechanism of action at macromolecular /sub cellular
organ systems.
A prerequisite for the design of safe drugs is knowledge about the various
metabolic reactions that xenobiotics and endogenous compounds undergo in the organism.
Because pharmacological activity depends on molecular structure, the medicinal chemist
is restricted in the choice of functional groups for the design of new drugs. Often he
finds or encounters a situation where a structure has adequate pharmacological  activity
but has an inadequate pharmacokinetic profile (i.e., absorption, distribution, metabolism
and excretion). This is because pharmacology and pharmacokinetic departments in the
pharmaceutical industry often do not collaborate at the early stage of drug development.
It is only later, when the new compound is tested in animals or in humans, that
pharmacokinetic disadvantages become obvious.
Modern drug discovery starts with the identification of a pharmacologic target
that is hypothetically the primary cause of disease. Potential targets include host cell
genes, receptors, signaling systems, organelles and biochemical such as enzymes.
Additionally, an element of a disease modifying process, such as an inflammatory
                           Introduction...
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mediator, may be a target. Biological processes required for propagation of infectious
agents have also proven to be therapeutically useful targets, examples include protease
and reverse transcriptase of the human immuno deficiency virus(HIV). Common to all
targets selected as therapeutic opportunities is the hypothesis that some type of
pathogenetic linkage exists to the disease causing process, rather than to specific signs,
symptoms or effects.
Heterocyclic compounds have great applicability in pharmaceutics because they
have specific chemical reactivity and provide false synthons in biosynthetic process or
block the normal functioning of biological receptors. The inhibition of amide resonance
resulting into more susceptibility of  β-lactam to nucleophile is considered at least in
part responsible for antibacterial property, apparently by acetylating transpeptidase and
thus inhibiting bacterial cell wall biosynthesis.
Most of the alkaloids which are nitrogenous bases occurring in plants and many
antibiotics including penicillin and streptomycin have also heterocyclic ring system. Many
natural pigments such as indigo, haemoglobin and anthocyanin are heterocycles. Most
of the sugars or their derivatives including Vitamin-C for instance, exist largely in the
form of five membered. Vitamin B
6
 (Pyridoxine) is a derivative of pyrimidine essential in
amino acid metabolism.
 The ultimate product of a successful drug design effort. Our goal for this is to
begin to deconvolute this information in order to apply it to design the new drugs.
Taking in view of the applicability of heterocyclic compounds, we have undertaken
the preparation of heterocycles bearing Imidazo [1,2-a] pyridine, dihydropyridine and
dihydropyrimidine nucleus.
AIMS AND OBJECTIVES
In the pharmaceutical field, there is a need for new and novel chemical inhibitors
of biological functions. Our efforts are focused on the introduction of chemical diversity
in the molecular frame work in order to synthesizing pharmacologically interested  heter
                           Introduction...
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ocyclic compounds of widely different composition. During the course of research work
looking to the applications of heterocyclic compounds, several entities have been
designed, generated and characterized using spectral studies. The aims and objectives
of the work carried out are as under.
 1. To synthesize pharmacologically active entities like chalcones, cyanopyridines,
pyrazolines, pyrimidinones, dihydropyridines, methylamines, etc.
 2. To characterise these products for structural elucidation using spectroscopic
techniques like IR, NMR and Mass spectral studies.
 3. To check the purity of all compounds using thin layer chromatography.
 4. To evaluate these new products for better drug potential against different
strains of bacteria and fungi.
In a programmed research directed towards the construction of therapeutically
active new heterocycles bearing  [A] Imidazo[1,2-a] pyridine,  [B] Dihydropyrimidine
and [C] Dihydropyridine nucleus has been investigated in following parts.
    [A]
STUDIES ON
IMIDAZO[1,2-a]PYRIDINES
        Imidazo[1,2-a]pyridines...
Studies on some compounds.... 015
INTRODUCTION
Bridge nitrogen containing fused heterocycles represents important
building blocks in both natural and synthetic bioactive compounds which have been shown
for possess diverse therapeutic activities1. Hence they are interesting target to be prepared
for our research on medicinally interesting heterocyclic entities. Aza-indolizine are of
two types, imidazo[1,2-a]pyridine (I) and imidazo[1,5-a]pyridine (II).
                              
N
N
                  
N
N
The aza-indolizine contains a phenyl ring fused to a imidazole ring is
indicated in the structure, hence it is also known as imidazo[1,2-a]pyridine2. Many drugs
contain imidazo[1,2-a] nucleus. Several procedures for their synthesis have been
extensively studied. Such studies have been stimulated by various promising applications,
especially in the case of bridgehead nitrogen containing fused heterocyclic entities.
The constitution of imidazo[1,2-a]pyridine was represented by W.
L.Mosby3. Imidazo[1,2-a]pyridine derivatives not only known for their medicinal
applications but they are also used in disperse dye4.
SYNTHETIC ASPECT
Several methods have been reported in the literature for the synthesis of
imidazo[1,2-a]pyridines. The procedure for synthesizing imidazo[1,2-a]pyridines have
been described as under.
1. The Tschitschibabine5 has synthesized imidazo[1,2-a]pyridine from 2-amino
( I )                                          ( II )
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     pyridine with ω-bromoacetophenone.
2. Paudler et al.6 have synthesized 5-amino-3-formyl imidazo[1,2-
a]pyridine from acid catalyzed hydrolysis of 1,4-diazatricyclo[3,2,2]azine.
     
N N
N H
+
H3O
+ N N
NH
HOH
N
N
NH2 O
3. Reaction of 2-chloropyridine with 1,2,3-triazoles and subsequent
elimination of nitrogens give imidazo[1,2-a]pyridine.7
    
N Cl
+
N
NNH
N
N
4. Groziak et al.8 have synthesized imidazo[1,2-a]pyridine by the condensa
-tion of 2-aminopyridine with glyoxal trimer dehydrate in aqueous NaHSO
3
.
       
N NH2
+
O
O
O
O
OH
OH
OH
OH
N
N
R
5. Imidazo[1,2-a]pyridine9 nucleus can be also synthesized by the reaction
of  α-ketohydrazidoyl halide with heterocyclic amines.
         
N NH2
+
CH3
O Br
N NH
Ar
N
N
CH3
N N
Ar
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6. Tsa i  e t  a l . 10 have  been  p repa red  3 -amino  imidazo[1 ,2 -
a]pyridinederivatives by a three component condensation reaction between
2-aminopyridine, aldehyde and an isonitrile in the presence of scandium
triflate as a catalyst.
                
H
O
R1 N NH2
R2 N
+
C-
Sc(OTF)3
N
N
R1
NH R2
+ +
   7.      Shawali et al.11 have synthesized imidazo[1,2-a]pyridine nucleus by the
             reaction of α-ketohydroximoylchloride with 2-aminopyridine.
      
N NH2
+ R
N
O
Cl
OH
N
N
R
NO
    8.     Ja´nos Gerencse´r 12 have direct Synthesis of Imidazo[1,2-a]pyridin-3-yl-
              carboxylic Acid Derivatives via the Condensation of 2-Amino-5-chloropyridine
            and Ethyl 4-Bromo-5-oxo-5-phenylpentanoate.
     +N
NH2
Cl
COOEt
Br
O
N
N
Cl
COOEt
MECHANISM
The majority of  imidazo[1,2-a]pyridine have been synthesized by  2-amino
pyridine with a-halocarbonyl compound which  cyclise at room temperature.
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N
NH2
R
R1 R2
X O
N
+
NH2
R1
R2
O
R-HX
NR
N
R2
R1
+
R, R1, R2 = Aryl,    X = Halide
THERAPEUTIC IMPORTANT
Imidazo[1,2-a]pyridines are potential bioactive agents due to their wide spectrum
of therapeutic importance. A large number of substituted imidazo[1,2-a]pyridine
derivatives are prepared and tested for varieties of biological activities. Some of them
are as under.
1.      Antiulcer13
2.      Long-acting local anaesthetic14
3.      Antiviral15,16
4.      Hypnotic17
5.      Antianxiety18
6.      Antibacterials19,20
7.      Antifungal agents21
8.            Calcium channel blockers22
9.            Antiherpetic activity23,24
10.          Anti-inflammatory, analgesic, antipyretic25,26
11.          Gastric antisecretory27,28
12.          Hypnoselective and anxioselective activities29
13.          β-Amyloid formation inhibitors30
14.          Active nonpeptide bradykinin B
2
 receptor antagonists31
        Imidazo[1,2-a]pyridines...
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15.          Nonsedative anxiolytic32
16.          Benzodiazepine receptor agonists33
17.          Anticytomegalo-zoster and antivaricellazoster virus34-36
18.          Cardiotonic agents37
19.          Anthelmintic38
Some imidazo[1,2-a]pyridines are already in market include alpidem39 [a ligand
of both the central benzodiazepine receptors and the peripheral type benzodiazepine
receptor] has sedative and anxiolytic properties and zolpidem39  [a selective ligand for
the central benzodiazepine receptor] is a hypnotic drug. Both alpidem and zolpidem
have higher affinity for enzodiazpine-1 than for benzodiazepine-2 receptors40 and their
interaction with various receptor types has been reported41.
      
N
N
Cl
Cl
O
N
CH2-CH2-CH3
CH2-CH2-CH3
N
N
CH3
CH3
O
N
CH3
CH3
James J. Kaminski and co-workers42 have investigated the imidazo[1,2-a]pyridine
derivative 3-(cyanomethyl)-2-methyl-6-(phenylmethoxy)imidazo[1,2-a]pyridine (III) as
an antiulcer agent. On the basis of the reported metabolism of zolimidine, they reported
that the 3-cyanomethyl and 6-phenylmethoxy group have been established as metabolic
sites.
      N
NO
NCH2C
CH3
    
N
N
S
O
O
CH3
 Alpidem                                        Zolpidem
      (III)                                     Zolimidine
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Pharmaceutical research requires an increasing number of novel compounds to cover
previously unexplored areas in the chemical space. There is also a need to increase the
quality of the newly prepared molecules regarding their drug likeness and other pre-
defined physicochemical parameters. Alexander C. Humphries and co-workers43 have
synthesized 8-fluoro imidazo[1,2-a]pyridine derivatives (IV).
                                         
N
N
FOH
CH3
CH3
F
NC
                          
N
N
O Br
CH3
ClCl
N
CH3
O
NH
O
N
O
CH3
CH3
 Evaluated as a bioisosteric replacement for imidazo[1,2-a]pyridine in an allosteric
modulator ligand of the GABA receptor. Kristian S. Gudmundsson44 have reported the
synthesis and antiviral activities of newer Erythrofuranosyl imidazo[1,2-a]pyridine C-
nucleosides. I. Aramori et al.45 have been synthesized highly potent and selective non-
peptide bradykinin receptor antagonist (V). A novel class of orally active non-peptide
bradykinin B
2 
receptor antagonist and discovering bioisosteres of the imidazo[1,2-
a]pyridine moiety reported by Yoshito Abe.46Synthesis of acyclo-c-nucleosides in the
    (IV)
 (V)
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imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.47  Dubinsky B and Vaidya
AH 48 has defined like imidazo [1,2-a] pyridine derivatives is a new nonbenzodiazepine
anxiolytic.
The  imidazo[1,2-a]pyridine bearing  a  very  good  synthon variety  of   building
blocks  in both natural and synthetic bioactive compounds.49-51 Mohamed A. Ismail 52
have  recently synthesized some novel  diamidine imidazo[1,2-a]pyridine like (VI) and
(VII) and 5,6,7,8-tetrahydro imidazo[1,2-a]pyridines and their corresponding N-hydroxy
and  N-methoxy analogues which  are  potential  for this series and their evaluation
versus  trypanosoma b. rhodesiense  and  plasmodium  falciparum. Moreover
synthesized  aromatic diamidines  exhibit  broad spectrum antimicrobial activity  including
effectiveness  against the protozoa53 disease caused by trypanosoma  SP and
plasmodium SP. Novel substituted imidazo [1,2-a] pyridine compounds are disclosed
which have a high degree of anthelmintic activity. Processes for the preparation of such
compounds are also disclosed as well as active ingredients for the treatment of
helminthiasis and anti ulsurative.
                              
N
N
O
NH2
NH
NH
NH2
R
a - R: H
b - R: Me
    
NH2
NH
N
N
NH
NH2
R
a - R: H;  pera connection
b - R: H;  meta connection
(VI)
(VII)
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 Kristjan S., Gudmundsson, Brian Johns A.54 and  Chaouni Bendallay A. et al.55 have
worked on synthesis of a novel imidazo[1,2-a] pyridine shown in (VIII) with potent
activity against herpes simplex viruses.
     
N
N
NH
N
N
NH
F
Thus the important role displayed by imidazo[1,2-a]pyridine and its derivatives
for various therapeutic and biological activities prompted us to synthesise some chalcones,
Phenylpyrazolines, cyanopyridines, thiozolidinones, cyclohexenone, schiff’s base, aryl
amino methyl derivatives bearing imidazo[1,2-a]pyridine moiety in order to get com-
pounds having better biological activities as described in the following parts.
STUDIES ON IMIDAZO[1,2-a]PYRIDINE DERIVATIVES
PART-I : STUDIES ON PYRAZOLINES
PART-II : STUDIES ON CYCLOHEXENONES
PART-III : STUDIES ON CYANOPYRIDINES
PART-IV : STUDIES ON ARYLAMINOMETHYL
DERIVATIVES
(VIII)
    PART - I
STUDIES ON
PYRAZOLINES
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INTRODUCTION
The term “chalcone” was first coined by Kostanecki and Tambor56. The
chemistry of chalcones has generated intensive scientific studies throughout the world.
Chalcones are coloured compounds because of the presence of the chromophore and
auxochrome. They are known as benzala cetophenones or benzylidene acetophenones.
Chalcones are characterized by their possession of a structure (I) in which two aromatic
rings (i) and (ii) are linked by an aliphatic three carbon chain.
                                                   OR1
R
(i)
(ii)
The alternative names given to chalcones are phenyl styryl ketones,
benzalacetophenone, β-phenyl acrylphenone, γ-oxo-α, γ-diphenyl-α-propylene and α-
phenyl-β-benzoethylene.
SYNTHETIC ASPECT
A considerable variety of methods are available for the synthesis of chalcones.
The most convenient method is the one that involves the Claisen-Schmidth condensation
of aryl methyl ketones with aryl aldehyde in the presence of  alkali57--58.
Several condensing agent used for the synthesis of chalcones are alkali of different
strength59-60, HCl61-62, Phosphorous oxychloride63, Piperidine64, Anhydrous Aluminium
Chloride65, Boron trifluoride66,  Aminoacids67, Perchloric acid68 etc.
( I )
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MECHANISM
The following mechanisms have been suggested for the synthesis of chalcone.
Carbanion formation observes in presence of alkali media and the intermediate aldol
type products formed readily undergoes dehydration even under mild condition and form
unsaturated  α-keto derivatives.
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REACTIVITY OF CHALCONES
The chalcones have been found to be useful for the synthesis of many heterocyclic
compounds.
1. Chalcones are intermediate compounds for the synthesis of some naturally
occurring heterocyclic compounds like flavones, flavanones, flavanoid,
dihydro flavanols, benzal coumarones, anthocyanine, etc.
2. Chalcone contain a Keto-Ethylenic group and therefore reactive towards a
number of reagents yielding various heterocyclic compounds exhibiting
significant biological activities viz. pyrazolines69, cyanopyridines70,
cyanopyrans71, cyanopyridones72, pyrimidines73-77, indazoles78 etc.
3. They have been useful in providing structure of some natural products like
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hemlocktanin79, narighenin80, plioretin81 etc.
4. Chalcones are also useful for the detection of Fe(II)82 and Ca(II)83 ions in
presence of Ba and Sr as it reacts with number of metal ions. Trihydroxy
chalcones was used as an analytical reagent for amperometric estimation of
copper84 and for spectrophotomatric study of the germanium85.
5. Chalcone and their derivatives are also found to be applicable as light
stabilizing agent86, sweetening agent87, organic brightening agent, photo
sensitive material, polymerisation catalyst, scintillators as well as  fluorescent
whitening agent.
6. The chalcones are natural biocides88-89 and are well-known key intermediate
in the synthesis of heterocyclic compounds possessing biodynamic behaviors.
THERAPEUTIC IMPORTANCE
Chalcone derivatives have been found to possess wide range of therapeutic
activities as shown below
1. Antiallergic90
2. Antiinflammatory91-92
3. Antitumor93-94
4. Antispasmodic95
5. Antiulcer96-97
6. Anthelmintics98-99
7. Anticancer100-101
8. Antiviral and Antitubercular102
9. Anti HIV103
10. Bactericidal104-105
11. Cardiovascular106
12. Fungicidal107-109
13. Herbicidal110
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14. Insecticidal111-113
Chalcones are potential biocides because some naturally occurring antibiotics114
and showing their biological activity in the presence of the α,β-unsaturated carbonyl
group. Nelson G. L.115 has synthesized the analogues of prostaglandin (II).
.                
O
R1
O
R            
X
O
ROH
X - NCH3/S
R - H/OCH3
Prem P. Yadav and co-workers116 have synthesized nitrogen and sulfur containing
furanoflavonoids and thiophenylflavonoids (III), Which have been screened for antifungal
and antibacterial activity. Meng C. Q. et al.117discovered some novel heteroaryl
substituted chalcones as inhibitors of TNF-alpha-induced VCAM-1 expression.
Some dihydrochalcones are well known for their sweetening property118-119 and
appear to be non-nutritive sweeteners. A dihydrochalcone Uvaretin from Uvaria
acuminata has shown antitumor activity120 in lymphocytic leukemia test.  AhluwaliaV.
K. et al.121 have noted that 5-cinnamoylchalcones (IV) have shown good  antibacterial
activity.
                           
OO
R
R1
R
R1
OH
OH
OH
Paula Boeck et al.122 have synthesized novel chalcone analogues (V) with
(II)     R, R1  = Aryl                   (III)
        (IV) R, R1 = Aryl
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pharmacological activity. Analogues containing nitro, fluorine or bromine group
respectively displayed increased activity against the parasites as compared with natural
chalcone.
                                
O
R1
R2
OH
R3
H3CO OCH3
R1=NO2, R2=H, R3=H
R1=H, R2=F, R3=H
R1=NO2, R2=H, R3=Br
Furthermore, Alcaraz M. J. et al.123 have described the role of nuclear
factor-kappaB and heme oxygenase-1 in the mechanism of act ion of  an
antiinflammatory activity of chalcone derivative. Nerya O. et al.124 have prepared
chalcones as potent tyrosinase inhibitors. Sabzevari O. et al.125 have constructed some
new chalcone derivatives (VI) as molecular cytotoxic mechanisms for anticancer activity.
Aneta Modzelewska et al.126 have prepared novel chalcone and bis chalcone derivatives
(VII) having anticancer activity.
    
O
OOMe
OH
OMe
                                 
N
R
R'R'
OCOR"
(V)
         (VI)
         (VII)
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Chalcones have been proved to be an important intermediate for the synthesis of
many heterocyclic compounds in organic chemistry. These facts prompted us to synthesize
some new chalcone derivatives bearing imidazo[1,2-a]pyridine as a nucleus. We have
prepare pyrazoline nucleus from chalcone, which are widely used in pharmaceutical field.
The study of pyrazoline nucleus is as under.
INTRODUCTION
The chemistry of pyrazoline was reviewed by Jarobe in 1967, which have been
studied extensively for their biodynamic behavior127. Pyrazoline have an important
heterocyclic compounds have been extensively explored for their applications in the
field of medicine.Pyrazoline has three possible tautomeric structures, but the structure
(I) shown is the most stable. Amongst nitrogen containing five member heterocycles,
pyrazolines have proved to be the most useful frame work for biological activities.
                                                    
N
H
N
SYNTHETIC ASPECT
Different methods for the preparation of 2-pyrazoline derivatives are as follows.
1. 2-Pyrazolines can be synthesized by the cycloaddition of diazomethane to
substituted chalcone128.
2. Dipolar cycloaddition of nitrilimines of dimethyl fumarate, fumaronitrile and
the N-aryl maleimides yielded the corresponding pyrazolines129.
3. Epoxidation of chalcones with epoxy ketones on reaction with hydrazine
hydrate and phenyl hydrazine to give pyrazolines130.
4. 2-Pyrazolines can be constructed by the cyclocondensation of chalcones with
(VII)
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hydrazine hydrate131.
                    
R R1
O
NH2.NH2.H2O
N
H
NR
R1
 5. 2-Pyrazolines can also be prepared by the condensation of chalcone dibromide
with hydrazine132. Furthermore, Gyassi B. et al133 have investigated the one pot
synthesis of some pyrazolines in dry media under microwave irradiation.  Paul
S.et al134 and Dandia Anshu et al135 have also described the microwave  synthesis
of 2-pyrazolines.
MECHANISM
The following mechanism for pyrazoline by the condensation of chalcones with
hydrazine hydrate136.
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H
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Nucleophilic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl
system forms species (III). Another intramolecular nucleophilic attack by the primary
amino group of ketoamine on its carbonyl carbon followed by proton transfer from
nitrogen to oxygen leads ultimately to carbonyl amine (IV). Later with a hydroxy group
and amino group on the same carbon lose water molecule to yield the pyrazolines. The
study of pyrazoline nucleus are as under.
THERAPEUTIC IMPORTANCE
From the literature survey, it was revealed that pyrazolines are better therapeutic
agents. Some of the activities are mentioned below.
1. Cardiovascular137
2. Diuretic138
3. Fungicidal139
4. Herbicidal140
5. Hypoglycemic141
6. Insecticidal142
7. Tranquilizer143
8. Antitumor144
9. Antineoplastic145
10. Antimicrobial146
11. Analgesic147-148
12. Bactericidal149,150
13. Antiallergic151
14. Anticonvulsant152-153
15. Antidiabetic154
17. Antiinflammatory155
18. Antiamoebic156
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Abdalla M. M. et al.157 have synthesized pyrazolines and tested their
antiandrogenic activity. Berghot M. A. et al.158 have prepared pyrazolines as antibacterial
agents. Maurer Fritz et al.159 have synthesized pyrazoles and screened for their pesticidal
activity.
Palaska E. et al.160 have prepared 3,5-diphenyl-2-pyrazolines (VIII) and cited
their antidepressant activity. Gokhan N.et al.161 reported pyrazolines as cholinstearase
and selective monoamine oxidase β−inhibitiors Stavenson T.M.et al.162 have also
investigated N-substituted pyrazoline type insecticides. Katsushori T.163 have patented
pyrazoline derivatives as herbicides and Johannes et al.164 have reported as
insecticides.
                    
N NH
R1
R2
OMe
OMe
Bhat and co-workers 165  synthesized pyrazoline derivatives, which have cytotoxic
properties. Rajendra prasad Y. et.al.166 have synthesized  some 1,3,5-tryphenyl 2-
pyrazoline and 3-[(2-hydroxy  napthaline)-1-yl ]-1,5-di phenyl 2-pyrazoline and reported
as antidepresent(IX) & (X).
       N N
R1
R2
R3
R4
N N
R2
R3
OH
R1
R4
R1= H,Cl,Br,Me,OMe
R2= H,Cl  (VIII)
       (IX)                   R1,R2,R3,R4 = Alkyl                (X)
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Mohmmad Abid and Amir Azam167 have synthesized pyrazoline (XI) and reported
as anti amoabic agent. Abd El.Galil E.Amr et.al 168 have screened some new 3-substituted
pyrazolines (XII)and reported their antiandrogenic activity.
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Almstead J. et al.169 have prepared pyrazolines as vascularization agent. Guniz
Kucukguzel et al.170 have synthesized pyrazolines as a anticonvulsant agents. Gulhan
T.Z.  and coworkers171 have prepared pyrazolines as a hypotensive agent. Shalabh Sharma
et al.172 have synthesized pyrazolines and tested their anti-inflammatory activity (XIII).
Ashok Kumar et al.173 have synthesized pyrazolines as anticonvulsant agents (XIV).
Maurer Fritz et al.174 have synthesized pyrazoles and screened for their pesticidal activity.
        
N
H
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OCH3COCH3
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       (XI)           R1,R2 = Aryl
(XII)                 R1,R2,R3 = Alkyl
(XIII)                                              (XIV)
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Shivarama B. Holla et al.175-176 have synthesized pyrazolines as antibacterial agent.
Hiremath S. P. et al.177 have synthesized pyrazolines as analgesic, anti-inflammatory and
antimicrobial agent. Malhotra V. et al.178 have synthesized new pyrazolines as a
cardiovascular agent (XV).
                                                
N
N
NH R2
S
R1
Ph
Moreover, Ahn J. H. et al.179 have described the synthesis and DP-IV inhibition
of cyano-pyrazoline derivatives as potent antidiabetic agents(XVI). Jeong T. S. et al.180
have synthesized some novel 3,5-diaryl pyrazolines as cholesterol acyl transferase in-
hibitors. Nasr M. N. et al.181 have reported the synthesis of Novel 3,3a,4,5,6,7-
hexahydroindazole and aryl thiazolylpyrazoline derivatives as  antiinflammatory agents.
Berghot M. A. et al.182 have prepared for antibacterial activity of pyrazole and pyrazoline
derivatives of diazepam.
                              N
NC
NH
NH
N
N
CNO
Recently, Gokhan N. et al.183 have synthesized the pyrazoline derivatives of 1-
N-substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines as MAO inhibitors.
Matysiak J. et al.184 have reported some novel pyrazoline derivatives having antipsycotic
activity. Tabarelli Z. et al.185 have prepared some pyrazole derivative showed activity of
antinociceptive effect of novel pyrazolines derivatives.
Novel bis(1-acyl-2-pyrazolines) are synthesized by Flora F. Barsoum186 & co-
  R1,R2 = Aryl         (XV)
         (XVI)
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workers for potential anti-inflammatory and molluscicidal properties. Mohammad Shahar
ya187 & co-workers synthesized and evaluated of pyrazoline derivatives (XVII)as anti-
bacterial agents.
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With a view to get better therapeutic agent, it was contemplated to synthesize
pyrazoline derivatives to enhance the overall activity of resulting compounds which have
been described as under.
SECTION-I   :  SYNTHESIS AND BIOLOGICAL SCREENING OF 1-
     ARYL-3-[6-METHYL-2-(4-METHYLPHENYL) IMIDAZO [1,2-
     a] PYRIDIN-3-YL]PROP-2-ENE-1-ONES
SECTION-II  :   SYNTHESIS AND BIOLOGICAL SCREENING OF 3-(3-ARYL-
     4,5-DIHYDRO-1H-PYRAZOL-5-YL)-6-METHYL-2-(4-
     METHYLPHENYL)IMIDAZO[1,2- a]PYRIDINES
SECTION-III  : SYNTHESIS AND BIOLOGICAL SCREENING OF 3-(3-ARYL-
     1-PHENYL-4,5-DIHYDRO-1H-PYRAZOL-5-YL)-6-METHYL-
               2-(4-METHYLPHENYL)IMIDAZO [1,2-a]PYRIDINES
 (XVII)            R = Aryl
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-ARYL-3-[6-METHYL-
2-(4-METHYLPHENYL) IMIDAZO [1,2-a] PYRIDIN-3-YL]PROP-2-ENE-1-
ONES
With the biodynamic activities of chalcones and it is a good synthon for various
heterocyclic rings, the interest has been focussed on the synthesis of new chalcones.
With a view to obtain compounds having better therapeutic activity, we have synthesized
1-Aryl-3-[6-methyl-2-(4-methylphenyl)imidazo [1,2-a]pyridin-3-yl]prop-2-ene-1-ones
type-(I) by the condensation of 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-
3-carbaldehyde with various aromatic ketones in the presence of  NaOH.
   
N
N
CH3
CH3
O
N
N
O
CH3
CH3
R
RCOCH3
NaOH
The structure elucidation of synthesized compounds have been characterized by
using elemental analysis, IR spectra, 1H NMR spectroscopy and further supported by
Mass spectrometry.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg. The biological
activities of synthesized compounds were compared with standard drugs. The details
have been cited in (A), part-I, section-I(E), page no.047.
   Type (I)       R=Aryl
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REACTION SCHEME
   Type-(I)                                     R = Aryl     
50 oC
60 oC
DMF +  POCl3
                            Pyrazolines...
037Studies on some compounds....
IR SPECTRAL STUDIES OF 1-(4-METHOXYPHENYL)-3-[6-METHYL-2-(4-
METHYLPHENYL) IMIDAZO [1,2-a] PYRIDIN-3-YL]PROP-2-ENE-1-ONE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer ;  Frequency range :  4000-400 cm-1 (KBr disc)
              Vibration
                Mode                      Observed           Reported
Alkane C-H str. (asym) 2966            2975-2950 189
-CH3 C-H str. (sym) 2876            2880-2860   
 ,,
C-H i.p.def.(asym) 1453            1470-1435   ,,
C-H o.o.p.def(sym) 1352            1390-1370   ,,
Aromatic C-H  str. 3061            3090-3030 190
C=C str. 1503            1540-1480   ,,
Imidazo[1,2-a] C=N str. 1610            1612-1593   ,,
pyridine C-N str. 1110            1220-1020   ,,
α,β-unsatur. C=O str. 1682            1700-1640 189
ketone
Vinyl C=C str. 1536           1580-1550   ,,
Type Ref.
Frequency in cm-1
N
N
CH3
CH3
O
OCH3
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IR SPECTRAL STUDIES OF 1-(2,4-DICHLOROPHENYL)-3-[6-METHYL-2-(4-
METHYLPHENYL) IMIDAZO [1,2-a] PYRIDIN-3-YL]PROP-2-ENE-1-ONE
  Instrument : SHIMADZU  FTIR  8400 Spectrophotometer ;  Frequency range :  4000-400 cm-1 (KBr disc)
 Observed
Alkane C-H str. (asym.)  2982 2975-2950        189
-CH3 C-H str. (sym.)  2864 2880-2860  ,,
C-H i.p.def. (asym.)  1450 1470-1435  ,,
C-H o.o.p. def. (sym.)  1362 1390-1370  ,,
Aromatic C-H  str.  3067 3090-3030        190
C=C str.  1509 1540-1480  ,,
Imidazo[1,2-a] C=N str.  1614 1612-1593  ,,
pyridine C-N str.  1170 1220-1020  ,,
α,β-unsaturated C=O str.  1699 1700-1640        189
ketone
Vinyl C=C str.  1559 1580-1550  ,,
C=C-H str.  3017 3050-3000  ,,
Type        Ref.
        Reported
Frequency in cm-1      Vibration
         Mode
N
N
CH3
CH3
O
Cl
Cl
                            Pyrazolines...
039Studies on some compounds....
NMR SPECTRAL STUDIES OF 1-(4-METHOXYPHENYL)-3-[6-METHYL-2-(4-
METHYLPHENYL) IMIDAZO [1,2-a] PYRIDIN-3-YL]PROP-2-ENE-1-ONE
  1      2.41   3H       singlet       Ar-CH3(j)       -
  2      2.43   3H       singlet       Ar-CH3(k)             -
  3      3.85   3H       singlet      Ar-OCH3(l)            -
  4  6.91-6.95   2H      doublet       Ar-H(a-a’)     8.2
  5  7.16-7.20   1H      doublet         Ar-H(f)     9.0
  6  7.28-7.32   2H         dd       Ar-H(c-c’)           7.8
  7  7.40-7.48   1H      doublet      CH=CH(h)   15.6
  8  7.57-7.62   1H      doublet        Ar-H(e)    9.0
  9  7.65-7.69   2H      doublet       Ar-H(d-d’)          7.8
 10  7.89-7.93   2H      doublet      Ar-H(b-b’)    8.2
 11  8.10-8.18   1H      doublet      CH=CH(i)   15.6
 12      8.25   1H       singlet        Ar-H(g)      -
 Signal   Signal Position    Relative No     
Multiplicity 
       
Inference
             J Value
   No.          (δppm)            of protons                                                       In Hz
     Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer (200 MHz)
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EXPANDED AROMATIC REGION
MASS SPECTRAL STUDIES OF 1-(4-METHOXYPHENYL)-3-[6-METHYL-2-(4-
METHYLPHENYL) IMIDAZO [1,2-a] PYRIDIN-3-YL]PROP-2-ENE-1-ONE
N
N
CH3
CH3
O
O
CH3
m/z = 382
N
N
CH3
CH3
O
OCH3
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N
N
CH3
CH3
O OCH3
m/z = 382
N
N
CH3
CH3
OCH3
m/z = 365
N
N
CH3
O
H3CO
m/z = 291
N
N
CH3
CH3
C O
m/z = 275
C
O
OCH3
m/z = 135
N
N
CH3
CH3
HC m/z = 247
N
N
CH3
HCm/z = 232
N
N
CH3
CH3
m/z = 222
N
N
m/z = 115 m/z = 77
HC
CH
CH3
m/z = 65
MASS FRAGMENTATION
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NMR SPECTRAL STUDIES OF 1-(2,4-DICHLOROPHENYL)-3-[6-METHYL-2-(4-
METHYLPHENYL) IMIDAZO [1,2-a] PYRIDIN-3-YL]PROP-2-ENE-1-ONE
   1              2.42     3H         singlet         Ar-CH3(k)        -
   2              2.44     3H         singlet         Ar-CH3(l)             -
   3          7.00-7.09     1H        doublet         CH=CH(i)          16.2
   4          7.24-7.28     2H        doublet         Ar-H(d-d’)      7.8
   5          7.26-7.28     1H        doublet           Ar-H(g)       -
   6          7.34-7.35     1H        doublet           Ar-H(c)              -
   7          7.41-7.46     1H        doublet           Ar-H(f)      9.2
   8          7.46-7.47     1H        doublet           Ar-H(b)       -
   9          7.56-7.60     2H        doublet         Ar-H(e-e’)           8.0
  10         7.63-7.67     1H              doublet           Ar-H(a)       -
  11         7.83-7.92     1H        doublet         CH=CH(j)     16.2
  12             8.23     1H         singlet           Ar-H(h)       -
 Signal    Signal Position    Relative No     
Multiplicity
         
 Inference  
        J Value
   No.            (δppm)           of protons                                           In Hz
 Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER  Spectrometer (200 MHz)
N
N
CH3
CH3
O
Cl
Cl
a
b
c
d
d'
e
e'f
g
h
i
j
k
l
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EXPANDED AROMATIC REGION
MASS SPECTRAL STUDIES OF 1-(2,4-DICHLOROPHENYL)-3-[6-METHYL-2-(4-
METHYLPHENYL) IMIDAZO [1,2-a] PYRIDIN-3-YL]PROP-2-ENE-1-ONE
N
N
CH3
CH3
O
Cl
Cl
m/z = 421
N
N
CH3
CH3
O
Cl
Cl
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N
N
CH3
CH3
O
Cl
Cl
m/z = 420
N
N
CH3
O
Cl
Cl
m/z= 405
N
N
CH3
CH3
O
Cl m/z = 385
N
N
CH3
CH3
HC m/z = 247
N
N
CH3
CH3
m/z = 222
CH3
m/z = 92
N
N
CH3
CH3
O
m/z = 275
N
N
CH3
HC
m/z = 232
C-
Cl
Cl
O
m/z = 173
Cl
Cl
m/z = 146
HC
CH
CH3
m/z = 65
MASS FRAGMENTATION
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MICROBIOLOGICAL SCREENING
Method : Cup-Plate188
Gram positive bacteria : Staphylococcus aureus & Bacillus subtilis
Gram negative bacteria : Pseudomonas aeruginosa & E. coli
Fungi : Aspergillus niger
Concentration : 40µg
Solvent : Dimethyl sulfoxide (DMSO)
Standard drugs : Amoxicillin, Benzoyl Penicillin,Ciprofloxacin,
Erythromycin, Griseofulvin.
The antimicrobial activity was compared with standard drugs as mentioned above.
The zone of inhibition was measured in millimeter.
ANTIMICROBIAL ACTIVITY
The purified products were screened for their antimicrobial activity using cup-
plate188 agar diffusion method. The control was with 0.04ml (40µg) of sample in DMSO.
In cause of antibacterial activity, the plates were incubated at 37oC for 24 hrs and for
antifungal activity the plates were incubated at 30 oC for 48 hrs.
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-ARYL-3-[6-METHYL-2-
(4-METHYLPHENYL) IMIDAZO [1,2-a] PYRIDIN-3-YL]PROP-2-ENE-1-ONES
[A] Synthesis of  6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine :
Align 1.0 lit 4/N RBF equiped with over head stirrer with condensor. Charged
100ml methanol and 21.3g (0.1 mol) 4-Methylphenyl acetyl bromide and then charged
11.9g (0.11mol) 5-Methyl-2-amino pyridine at room temperature stirr till clear solution
obtained then lot wise 5.9g (0.055mol) Na2CO3  was added at room temperature. After
complition of addition heated at 50 oC for 30 min then checked TLC.  The reaction
mixture was allowed to cool to room temperature and poured into 1.0 lit water. The
formed solid was collected by filtration, washed with water, dried and crystallized from
the isopropyl alcohol. Yield 86%, m.p. 209 oC.
[B] Synthesis of 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-
carbaldehyde :
Align 2.0 lit 4/N RBF equiped with over head stirrer with condensor on water
bath. Charged 84ml DMF and 1.0 lit CHCl3 into RBF. It was cooled at 0 - 5 
oC
temperature. Slowly added 165ml POCl3  within 1.0 h. During addition the exothermicity
was controlled. Temperature raised at 10-15 oC and stirred for 30 minutes. 50g (0.225
mol) of 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine was added slowly, temp
raises, refluxed for 6 hrs. CHCl3 was removed by vacuum distillation and reaction mass
cooled at room temperature, poured into 2.0 lit ice cold water. Neutral pH adjusted
bellow  room temperature with the help of mild coustic solution. The solid mass was
collected by filtration, washed with water, dried and crystallized from the methanol. Yield
80%, m.p. 152 oC.
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[C] Synthesis of 1-(4-Methoxyphenyl)-3-[6-methyl-2-(4-methylphenyl) imidazo
[1,2-a] pyridin-3-yl]prop-2-ene-1-one :
6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde 2.5g
(0.01mol) was dissolved in 25 ml methanol at room temperature. p-Methoxy
acetophenone 1.40g (0.01mol) and 0.2 ml 40% sodium hydroxide solution was added.
Stirred the content at room temperature for 24 hrs then filtered it and washed with
chilled methanol. Yield 76 %, m. p. 200 oC, Elemental Analysis Calcd for C25H22N2O2
Requires : C-78.51%, H-5.80%, N-7.32%, Found : C-78.40%, H-5.72%, O-7.35%.
[D] Synthesis  of 1-(2,4-Dichlorophenyl)-3-[6-methyl-2-(4-methylphenyl)
imidazo [1,2-a] pyridin-3-yl]prop-2-ene-1-one :
6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde 2.5g (0.01mol)
was dissolved in 25 ml methanol at room temperature and stirred till clear solution
obtained. 2,4-Dichloro acetophenone 1.9 gm (0.01mol) and 0.2 ml 40% sodium
hydroxide solution was added. Stirred the content at room temperature for 24 hrs then
filtered it and washed with chilled methanol. Yield 68 %, m.p.205 oC, Elemental Analalysis
Calcd for C24H18Cl2N2O Requires : C-68.42%, H-4.31%, N-6.65%,  Found : C-68.40%,
H-4.12%, N-6.50 %.
Similarly, other 1-Aryl-3-[6-methyl-2-(4-methylphenyl) imidazo [1,2-a] pyridin-3-
yl]prop-2-ene-1-ones compounds were prepared. The physical data are recorded in table.01
[E] Biological screening of 1-Aryl-3-[6-methyl-2-(4-methylphenyl) imidazo
[1,2-a] pyridin-3-yl]prop-2-ene-1-ones :
(a) Antibacterial activity :
The purified products were screened for their antibacterial activity using cup-
plate agar diffusion method. The nutrient agar broth prepared by the usual method was
inoculated aseptically with 0.5 ml of 24hrs old subcultures of Bacillus subtilis,
Staphylococcus aureus, E.coli, Pseudomonas aeruginosa in separate conical flasks
at 35-40 oC and mixed well by gentle shaking. About 25 ml content of the flask was
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poured and evenly spreaded in a sterilized petridish (13 cm diameter) and allowed to
set for 2 hrs. The cups (10 mm diameter) were formed by the help of borer in agar
medium and filled with 0.04ml (40µg) solution of sample in DMSO. The plates were
incubated at 37oC for 24 hrs and the control was also maintained with 0.04ml of DMSO
in a similar manner and the zone of inhibition of the bacterial growth were measured in
millimeter and recorded in graphical chart no.1.
(b) Antifungal activity :
Aspergillus niger was employed for testing antifungal activity using cup-plate
agar diffusion method. The culture was maintained on sabouraud’s agar medium. Sterilized
sabouraud’s agar medium was inoculated with 72 hrs old 0.5ml suspension of fungal
spores in a separate flask. About 25 ml of the inoculated medium was evenly spreaded
in a sterilized petridish (13cm diameter) and allowed to set for 2 hrs. The cups (10mm
diameter) were punched in petridish and loaded with 0.04ml (40µg) of solution of sample
in DMSO. The plates were incubated at 30 oC for 48 hrs.  After the completion of
incubation period, the zone of inhibition of growth in the form of diameter in mm was
measured. Along the test solution in each petridish one cup was filled up with solvent,
which acts as control. The zones of inhibition of test solutions  are recorded in graphical
chart no.01.
Conclusion :
Antibacterial activity
The screening data indicated that among chalcone derivatives tested compounds
1b,1f,1j,1l showed greater degree of antibacterial activity against S.aureus. However,
the compounds 1b,1c,1g,1k showed greater degree of antibacterial activity against
B.subtilis. The compounds 1a,1e,1g,1h and 1l showed greater degree of antibacterial
activity against E.coli  and P. aeruginosa respectively.
Antifungal activity
The screening data indicated that among chalcone derivatives tested compounds
1h,1i showed greater degree of antifungal activity against A.niger.
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SECTION - II
SYNTHESIS AND BIOLOGICAL SCREENING OF  3-(3-ARYL-4,5-DIHYDRO-
1H -PYRAZOL-5-YL)-6-METHYL-2-(4-METHYLPHENYL)IMIDAZO[1,2-
a]PYRIDINES
The broad spectrums of pharmacological properties have been demonstrated by
the pyrazoline nucleus. Inspired by these facts, new pyrazoline derivatives of type (II)
have been investigated. 1-Aryl-3-[6-methyl-2-(4-methylphenyl) imidazo [1,2-a] pyridin-
3-yl]prop-2-ene-1-ones type (I) treated with hydrazine hydrate in methanol to afford 3-
(3-Aryl-4,5-dihydro-1H-pyrazol-5-yl)-6-methyl-2-(4-methylphenyl)imidazo [1,2-
a]pyridines derivatives of type (II).
     
N
N
NH
N
CH3
CH3
R
N
N
O
CH3
CH3
R
NH2NH2   H2O
The structure elucidation of synthesized compounds have been characterized by
using elemental analysis, IR spectra, 1H NMR spectroscopy and further supported by
Mass spectrometry.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg. The biological
activities of synthesized compounds were compared with standard drugs. The details
have been cited in (A), part-I, section-I(E), page no.047.
          Type (I)                  R = Aryl                    Type (II)
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IR SPECTRAL STUDIES OF 3-[3-(4-METHOXYPHENYL)-4,5-DIHYDRO-1H-
P Y R A Z O L - 5 - YL]-6-METHYL-2-(4-METHYLPHENYL)IMIDAZO[1,2-
a]PYRIDINE
     
Type
   Vibration      Frequency in cm-1    
Ref.
     Mode                  Observed               Reported
   Alkane C-H str. (asym.) 2956  2975-2950    189
  -CH3 C-H str. (sym.) 2854  2880-2860      ,,
C-H def. (asym.) 1454  1470-1435      ,,
  Aromatic C-H  str. 3016  3090-3030    190
C=C str. 1517  1540-1480      ,,
C-H i.p. (def.) 1062  1125-1090      ,,
 820                   835-810                  ,,
  Methoxy C-O str. 1260  1260-1200      ,,
 Pyrazoline C=N str. 1608  1612-1593      ,,
N-H str. 3301  3400-3200      ,,
Imidazo[1,2-a] C=N str. 1568  1612-1593      ,,
  pyridine C-N str. 1033  1220-1020                ,,
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer ;  Frequency range :  4000-400 cm-1 (KBr disc)
N
NCH3
CH3
N
O CH3
NH
H
H
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NMR SPECTRAL STUDIES OF 3-[3-(4-METHOXYPHENYL)-4,5-DIHYDRO-
1H -PYRAZOL-5-YL]-6-METHYL-2-(4-METHYLPHENYL)IMIDAZO[1,2-
a]PYRIDINE
    Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer (200 MHz)
Signal  SignalPosition    Relative No     Multiplicity         Inference            J Value  No.         (δppm)           of protons                                                    In Hz
      1          2.27 3H singlet            Ar-CH3(n)         -
   2          2.39 3H      singlet        Ar-CH3(m)            -
   3       3.34-3.40            2H      doublet        Ar-H(i-j)            12.2
   4          3.85 3H      singlet        Ar-OCH3(k)      -
   5       5.58-5.77            1H     d.doublet        Ar-H(h)    12.2
   6       6.93-6.97            2H      doublet        Ar-H(a-a’)          8.6
   7       7.04-7.08            1H      doublet        Ar-H(f)     9.2
   8       7.24-7.27            2H      doublet        Ar-H(c-c’)     7.8
   9       7.50-7.54            2H      doublet        Ar-H(d-d’)          8.4
  10      7.54-7.59            1H      doublet        Ar-H(e)     9.6
  11      7.64-7.68            2H      doublet        Ar-H(b-b’)     8.6
  12         8.29                 1H      singlet         Ar-H(g)      -
N
NCH3
CH3
N
O CH3
NH
H
H
a
a'
b
b'
c
c'
d'
d
ef
g
ih
j
k
m
n
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EXPANDED AROMATIC REGION
MASS SPECTRAL STUDIES OF 3-[3-(4-METHOXYPHENYL)-4,5-DIHYDRO-1H-
P Y R A Z O L - 5 - YL]-6-METHYL-2-(4-METHYLPHENYL)IMIDAZO[1,2-
a]PYRIDINE
N
N
CH3
CH3
N
O
CH3
NH
m/z = 396
N
NCH3
CH3
N
O CH3
NH
H
H
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N
N
CH3
CH3
N
OCH3
NH
m/z = 396
N
N
CH3
CH3
N
O-
NH
m/z = 380
N
N
CH3
CH
CH
CH3
m/z = 247
N
N
CH3
CH3
m/z = 222
N
O
CH3
NH
m/z = 174
N
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 3-(3-ARYL-4,5-DIHYDRO-
1H-PYRAZOL-5-YL)-2-(4-METHYLEPHENYL)IMIDAZO[1,2- a]PYRIDINES
[A] Synthesis of  6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine :
See(A), part-I, section-I (A), page no.046.
   [B]    Synthesis of 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde:
See(A), part-I, section-I (B), page no.046.
[C] Synthesis of 1-(4-Methoxyphenyl)-3-[6-methyl-2-(4-methylphenyl)
imidazo [1,2-a] pyridin-3-yl]prop-2-ene-1-one :
See(A), part-I, section-I (C), page no.047.
[D] Synthesis of 3-[3-(4-Methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-6-
methyl-2-(4-methylphenyl)imidazo[1,2- a]pyridine :
A mixture of  1-(4-Methoxyphenyl)-3-[6-methyl-2-(4-methylphenyl) imidazo [1,2-
a] pyridin-3-yl]prop-2-ene-1-one 3.82 gm (0.01 mol) and hydrazine hydrate 1.0gm
(0.02mol) in 25 ml methanol was stirred for 4hrs at room temperature. The reaction
mass was kept overnight. Precipitated product was filtered out and recrystllized from
ethanol. Yield 72 %, m.p. 204 oC, Elemental Analalysis Calculated for C25H24N4O
Requires : C-75.73%, H-6.1%, N-14.14%, Found : C-75.64%, H-6.05%, N-14.12%.
Similarly, other 3-(3-Aryl-4,5-dihydro-1H-pyrazol-5-yl)-6-methyl-2-(4-methyl phe
nyl) imidazo[1,2- a]pyridines were prepared.The physical data are recorded in table no 02.
                            Pyrazolines...
057Studies on some compounds....
[E] Biological screening of 3-(3-Aryl-4,5-dihydro-1H-pyrazol-5-yl)-2-(4-
methylphenyl)imidazo[1,2- a]pyridines :
Antimicrobial testing was carried out as described in (A), part-I, section-I(E),
page no.047. The zones of inhibition of test solutions are recorded in graphical chart
no.02.
Conclusion :
Antibacterial activity
The screening data indicated that among simple pyrazoline derivatives tested
compounds 2c, 2f, 2l showed greater degree of antibacterial activity against S.aureus.
However, the compounds 2b, 2c, 2k showed greater degree of antibacterial activity
against B.subtilis. The compounds 2a, 2e, 2g, 2k, 2l and 2d, 2h showed greater degree
of antibacterial activity against E.coli  and P. aeruginosa respectively.
Antifungal activity
The screening data indicated that among simple pyrazoline derivatives tested
compounds 2a, 2k showed greater degree of antifungal activity against A.niger.
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SECTION - III
SYNTHESIS AND BIOLOGICAL SCREENING OF 3-(3-ARYL-1-PHENYL-
4,5-DIHYDRO-1H-PYRAZOL-5-YL)-6-METHYL-2-(4-METHYLPHENYL)
IMIDAZO [1,2-a]PYRIDINES
Various derivatives of phenyl pyrazoline exhibit interesting biological properties
like anticancer, antiinflammatory, anticonvulsant, antipyretic, etc. With a view to prepare
more potential drug value compounds, we have carried out the synthesis of phenyl
pyrazoline derivatives of type-(III), which have been prepared by the condensation of
chalcones of type-(I) with phenyl hydrazine in the presence of piperidine as a catalyst,
which have been briefed as under.
     
C6H5NHNH2
N
N
CH3
CH3
O
R
N
N
CH3
CH3
N
N
R
The structure elucidation of synthesized compounds have been characterized by
using elemental analysis, IR spectra, 1H NMR spectroscopy and further supported by
Mass spectrometry.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg. The biological
activities of synthesized compounds were compared with standard drugs. The details
have been cited in (A), part-I, section-I(E), page no.047.
          Type (I)                    R=Aryl                      Type (III)
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IR SPECTRAL STUDIES OF 3-[3-(2,4-DICHLOROPHENYL)-1-PHENYL-4,5-
DIHYDRO-1H-PYRAZOL-5-YL]-6-METHYL-2-(4-METHYLPHENYL)
IMIDAZO [1,2-a]PYRIDINE
     
Type
   Vibration      Frequency in cm-1    
Ref.
     Mode                  Observed               Reported
Alkane C-H str. (asym.) 2943  2975-2950    189
-CH3 C-H str. (sym.) 2843  2880-2860      ,,
C-H def. (asym.) 1433 1470-1435      ,,
C-H def. (sym.) 1388 1390-1370      ,,
Aromatic C-H  str. 3028 3090-3030    190
C=C str. 1500 1540-1480      ,,
C-H i.p. (def.) 1062 1125-1090      ,,
 817                   835-810                  ,,
Halide C-Cl str. 704 800-600      ,,
Pyrazoline C=N str. 1596 1612-1593      ,,
Imidazo[1,2-a] C=N str. 1560 1612-1593      ,,
pyridine C-N str. 1124 1220-1020                ,,
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer ;  Frequency range :  4000-400 cm-1 (KBr disc)
N
NCH3
CH3
N
Cl
N
Cl
H
H
                            Pyrazolines...
062Studies on some compounds....
NMR SPECTRAL STUDIES OF 3-[3-(2,4-DICHLOROPHENYL)-1-PHENYL-4,5-
D I H Y D R O - 1 H - P Y R A Z O L - 5 - Y L ] - 6 - M E T H Y L - 2 - ( 4 -
METHYLPHENYL)IMIDAZO [1,2-a]PYRIDINE
      Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer (200 MHz)
 Signal   Signal Position    Relative No    Multiplicity             Inference            J Value    No.          (δppm)           of protons                                                          In Hz
 1      2.24  3H     singlet          Ar-CH3(q)        -
 2      2.42  3H     singlet          Ar-CH3(r)                -
 3  3.63-4.09  2H    d.doublet          Py-H(i-j)           10.4
 4  5.90-5.96  1H      triplet          Ar-H(k)                -
 5  6.77-6.80  1H     d.doublet          Ar-H(g)       6.4
 6     6.91  1H      singlet          Ar-H(f)        -
 7     6.95  1H      singlet          Ar-H(c)        -
 8  7.02-7.06  2H     doublet         Ar-H(d-d’)       7.6
 9  7.26-7.28  1H     doublet          Ar-H(b)       5.0
10             7.32  3H      singlet        Ar-H(m,n,o)          7.0
11  7.49-7.53  1H     doublet          Ar-H(p-l)            9.4
12          7.59-7.63  2H     doublet         Ar-H(e-e’)       8.0
13      7.74  1H     singlet          Ar-H(h)        -
14   7.82-7.86  1H     doublet          Ar-H(a)       8.4
N
NCH3
CH3
N
Cl
N
Cl
H
H
b
c
d
e
fg
h
i
jk
l
d'
e'
a
m
n
o
p
q
r
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m/z = 510
N
NCH3
N
N
Cl
Cl
m/z = 420
N
NCH3
CH3
N
N
Cl
Cl
N
NH
N
NCH3
CH3
m/z = 288
N
N
Cl
Cl
m/z = 290
N
N
CH3
CH3
CH
m/z = 233
N
N
CH3
m/z = 130
N
N
CH3
CH3
HC m/z = 247
N
N
Cl
m/z = 253
Cl
Cl
m/z = 173
N
N
CH3
CH3
m/z = 222
CH3
m/z = 92
N
N
CH3
m/z = 130
HC
CH
CH3
m/z = 65
NH
N
m/z = 65
N
N
m/z = 145
Cl
m/z = 111
MASS FRAGMENTATION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF  3-(3-ARYL-1-PHENYL-4,5-
DIHYDRO-1H-PYRAZOL-5-YL)-6-METHYL-2-(4-METHYLPHENYL)
IMIDAZO [1,2-a]PYRIDINES
[A] Synthesis of  6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine :
See(A), part-I, section-I (A), page no.046.
[B]    Synthesis of 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde :
See(A), part-I, section-I (B), page no.046.
[C] Synthesis of 1-(2,4-Dichlorophenyl)-3-[6-methyl-2-(4-methylphenyl)
imidazo [1,2-a] pyridin-3-yl]prop-2-ene-1-one :
See(A), part-I, section-I (D), page no.047.
[D] Synthesis of 3-[3-(2,4-Dichlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-
5-yl]-6-methyl-2-(4-methylphenyl)imidazo [1,2-a]pyridine :
 A mixture of 1-(2,4-Dichlorophenyl)-3-[6-methyl-2-(4-methylphenyl) imidazo
[1,2-a] pyridin-3-yl]prop-2-ene-1-one 4.21gm (0.01 mol), phenyl hydrazine 1.18gm
(0.01 mol) and basic catalyst piperidine in 25ml methanol was refluxed for 28hrs.
Rreaction mass was poured into chilled water. Product was filtered and dryed. it was
recrystallized from ethanol. Yield 54 %, m.p.146 oC, Elemental Analysis Calculated for
C30H24Cl2N4 Requires : C-70.45%,  H-4.73%, N-10.95%, Found : C-70.34%, H-
4.75%, N-10.93%.
Similarly other 3-(3-Aryl-1-phenyl-4,5-dihydro-1H-pyrazol-5-yl)-6-methyl-2-
(4-methylphenyl)imidazo [1,2-a]pyridines  were prepared. The physical data are recorded
in table no.03.
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[E] Biological screening of 3-(3-Aryl-1-phenyl-4,5-dihydro-1H-pyrazol-5-yl)-
6-methyl-2-(4-methylphenyl)imidazo [1,2-a]pyridines :
Antimicrobial testing was carried out as described in (A), part-I, Section-I(E),
page no.047. The zones of inhibition of test solutions are recorded in graphical chart
no.03.
Conclusion :
Antibacterial activity
The screening data indicated that among phenylpyrazoline derivatives tested
compounds 3b, 3h, 3l showed greater degree of antibacterial activity against S.aureus.
However, the compounds 3b, 3c, 3g, 3h, 3k showed greater degree of antibacterial
activity against B.subtilis. The compounds 3k, 3l and 3h showed greater degree of
antibacterial activity against E.coli  and P. aeruginosa respectively.
Antifungal activity
The screening data indicated that among phenylpyrazoline derivatives tested
compounds 3a, 3k showed greater degree of antifungal activity against A.niger.
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    PART - II
STUDIES ON
CYCLOHEXENONE
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INTRODUCTION
Cyclohexenone is derivative of cyclohexane with carbonyl group at position-1
and double bond at position-2 (I). There are different types of cyclohexenone derivatives
but the greatest difference in structure and properties is exerted by the groups attached
to carbon atom.
                                                       
O
Cyclohexenone is the parent of a series of compounds which have an important
role in agricultural and medicinal chemistry. Cyclohexenones can be synthesized by the
treatment of α,β-unsaturated carbonyl compounds with ethyl acetoacetate in basic media.
In recent years cyclohexenone derivatives have gained lot of interest because of its
prominent pharmaceutical properties.
SYNTHETIC ASPECT
Different methods for the preparation of cyclohexenone derivatives have been
described in literature.191-204
(I) Shklyaev et al.205 have synthesized cyclo hexenone derivatives (II).
                                          
NH
O
CH3
COOEt
CH3
CH3
(II)
(I)
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 (II) Eman H. A. et al.206 have been prepared cyclohexenone derivatives (III) from
chalcones.
                            
NX S
O
O
O
R
NX S
O
O
O
COOEt
R
K2CO3 / Acetone
EAA
(III) In review of the earlier literature Gerald207 et al.have described representative
synthetic procedure of cyclohexenone derivatives (IV).
                                                   
O
(IV) Page Philip C. and co-workers208 have prepared substituted cyclohexenone
derivative (V).
                            
SS
CH3O
Et
O
SS
O
Methyl vinyl ketone
(V)
(III)
(IV)
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 MECHANISM
The addition reaction between ethyl acetoacetate and α,β-unsaturated ketone
give cyclohexenone via Michael addition. This reaction has been carried out in basic
media by using sodium ethoxide or anhydrous K2CO3 in acetone, during the reaction,
nucleophilic addition of carbanion takes place to the C=C of the acceptor. The α,β-
unsaturated compound is known as acceptor and ethyl acetoacetate is known as donor.
      
R
O
R1 R CH
CH C
O
R1
-
CH3
O
COOC2H5
CH3
O
CH COOC2H5
-
+ HOH
[A]
[A] + H+
R CH
O
R1
+
CH3CH
O
H5C2OOC
CH3
O
H5C2OOC
R R1
O
O
H5C2OOC
R R1
[B]
H2O
-
-
+
+
+
-
THERAPEUTIC EVALUATION
Cyclohexenone and its derivatives are widely used in pharmaceutical industries.
Considerable interest has been shown in the chemistry of cyclohexenones due to their
wide spectrum of therapeutic activities which are listed as under.
1. Herbicidal209
2. Analgesic210
3. Anti-inflammatory211
4. Anticonvulsant212
5. Antibacterial213
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6. Antagonist214
7. Antibiotic215
8. Cardiovascular216
Antimicrobial activity of cyclohexenones have been studied by Salama and
Atshikh.217  Cyclohexenone possess neutropeptide γ-receptor antagonist activity which
was reported by Takehiro and co-workers218.
Broughton Howard219 have demonstrated cyclohexenone as GABA A5 receptor
ligands for enhancing coagulating properties. Cyclohexenones possess inhibitory activity
against the growth of lettuce seeding found by Kimura and co-workers.220
Cyclohexenones have various medicinal applications as an antiarrhythmic
activity221 of some cyclohexenone derivatives have been investigated. Cyclohexenone
possess cardiovascular, osteoporosis, menpausal symptoms, estrogen dependent etc.
Cyclohexenone and its derivatives have been prepared and reported as broad
spectrum of physiological properties viz., antibiotics,222-223  herbicidal,224 antimicrobial,225
etc. Alekseeva L. M. and co-workers226 have synthesized cyclohexenone derivatives
which are useful as neurotropic activity. Toshiyuki et al.227 have prepared some novel
cyclohexenone and screened for their allergy inhibitor, antithrombotic platelet aggregation
inhibitors and fibrinogen antagonist activity.
The presence of pesticidal activity among cyclohexenone derivatives is well
documented. The compound 2-[(E,Z)-1-[(2R,S)-2-(4-chlorophenoxy) propoxyimino]
butyl]-3-hydroxy-5-thian-3-yl)cyclohex-2-en)-one (VI) has been marketed under the
name of ‘Profoxydine’ as an herbicides.
Alan J. Anderson et al.228 have synthesized cyclohexenone derivative and studied
on the anticonvulsant activity and potential type (VII) phosphodiesterase inhibitor. Yasuko
Takahashi et al.229 have reported cyclohexenone derivatives and studied on novel g-
secretase inhibitor (VIII).
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                                     S
CH3OH
O N
O
O
CH3
                  O
NH O
R1 R2
   
N
O O
OH
O
Eddington N. D. et al.230 have synthesized ethyl 4-[(aryl)amino]-6-methyl-2-
oxocyclohex-3-ene-1-carboxylates  and screened their anticonvulsant activity. Cragoe,
Edward J. et al.231 have prepared 2,3-dihydro-5-(3-oxo-2-cyclohexen-1-yl)-2-
benzofurancarboxylic acids  and their salts which are used in the treatment of brain
injury. K. R. Scott et al.232 have synthesized cyclohexenone derivative (IX) and studied
on the anticonvulsant activity.
                                    
O N
NH
CH3
CH3
O
Vital contribution of Cyclohexenone ring system to the medicinal chemistry as an
active constituent of antibiotics made chemists to explore for its derivatives as therapeutic
agents. Accordingly, several derivatives of Cyclohexenone have been designed as under.
(VII)      0                                       (VIII)
   (IX)
(VI)
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 SECTION-I :   SYNTHESIS AND BIOLOGICAL SCREENING OF METHYL-4-
    ARYL-6-[6-METHYL-2-(4-METHYLPHENYL)IMIDAZO[1,2-
          a]PYRIDIN-3-YL]CYCLOHEX-2-ONE-3-ENE-1-CARBOXYL-
    ATES
SECTION-II :   SYNTHESIS AND BIOLOGICAL SCREENING OF  ETHYL-4-ARYL-
     6-[6-METHYL-2-(4-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-
    YL]CYCLOHEX-2-ONE-3-ENE-1-CARBOXYLATES
SECTION-III : SYNTHESIS AND BIOLOGICAL SCREENING OF  1-ACETYL-4-
    ARYL-6-[6-METHYL-2-(4-METHYLPHENYL)IMIDAZO[1,2-
    a]PYRIDIN-3-YL]CYCLOHEX-2-ONE-3-ENES
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SECTION-I
SYNTHESIS AND BIOLOGICAL SCREENING OF METHYL-4-ARYL-6-[6-
M E T H Y L - 2 - ( 4 - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 -
YL]CYCLOHEX-2-ONE-3-ENE-1-CARBOXYLATES
Cyclohexenone derivatives have considerable attention in view of their potential
pharmacological properties such as antimicrobial, anticonvulsant, anticancer, etc. led by
these considerations, the preparation of cyclohexenone derivatives of type-(IV) has been
undertaken. The synthesis was carried out by the condensation of 1-Aryl-3-[6-methyl -
2-(4-methylphenyl) imidazo [1,2-a] pyridin-3-yl]prop-2-ene-1-ones of type-(I) with
methyl acetoactate in the presence of basic catalyst like dry K2CO3  shown as under.
    
N
N
O
CH3
CH3
R
N
N
CH3
CH3
MeOOC
O
R
K2CO3
          MAA
The structure elucidation of synthesized compounds have been characterized by
using elemental analysis, IR spectra, 1H NMR spectroscopy and further supported by
Mass spectrometry.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg. The
biological activities of synthesized compounds were compared with standard drugs.
The details have been cited in (A), part-I, section-I(E), page no.047.
Type-(I)                                              Type-(IV)      R=Aryl
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IR SPECTRAL STUDIES OF  METHYL-4-(4-METHOXYPHENYL)-6-[6-
M E T H Y L - 2 - ( 4 - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 -
YL]CYCLOHEX-2-ONE-3-ENE-1-CARBOXYLATE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer ;  Frequency range :  4000-400 cm-1 (KBr disc)
Alkane C-H str. (asym.) 2952  2975-2950    189
-CH3 C-H str. (sym.) 2842  2880-2860       ,,
C-H def. (asym.) 1450 1470-1435       ,,
C-H def. (sym.) 1348 1390-1370       ,,
Aromatic C-H  str. 3045 3090-3030    190
C=C str. 1483 1540-1480       ,,
C-H i.p. (def.) 1093 1125-1090       ,,
 806                   835-810                   ,,
Methoxy C-O str. 1265 1260-1200       ,,
Cyclohex- C=O str. of ester 1738 1750-1725       ,,
enone C=O str.of cyclo. 1675 1720-1690       ,,
Imidazo[1,2-a] C=N str. 1595 1612-1593       ,,
pyridine C-N str. 1172 1220-1020                 ,,
   
Type
   Vibration      Frequency in cm-1  
  Ref.
     Mode                  Observed               Reported
N
N
CH3
CH3
O
MeOOC
O
CH3
H
H
H
H
H
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NMR SPECTRAL STUDIES OF METHYL-4-(4-METHOXYPHENYL)-6-[6-
M E T H Y L - 2 - ( 4 - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 -
YL]CYCLOHEX-2-ONE-3-ENE-1-CARBOXYLATE
       Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer (200 MHz)
   Signal   Signal Position    Relative No     Multiplicity          Inference            J Value      No.           (δppm)           of protons                                             In Hz
     1 2.37     3H   singlet   Ar-CH3 (o)                           -
     2 2.38     3H   singlet   Ar-CH3 (n)            -
     4         2.95-3.30     2H  doublet  Cyclo (l-k)            -
    3 3.51     3H   singlet  O=C-O-CH3            -
     5 3.84     3H  singlet   Ar-OCH3                       -
     6          4.07-4.11     1H  doublet    Cyclo(i)          13.6
     7          4.30-4.38     1H  multiplet    Cyclo(h)            -
     8             6.52     1H  singlet    Cyclo(j)            -
     9          6.89-6.94     2H  doublet   Ar-(a-a’)          8.6
    10          7.05-7.096     1H  doublet    Ar-H (f)          9.0
    11             7.22-7.26     2H  doublet   Ar- (c-c’)          7.8
    12          7.57-7.61     1H  doublet     Ar-(e)          8.8
    13          7.47-7.50     4H  doublet  Ar-(b,b’-d,d’)         7..2
    14              7.98    1H   singlet      Ar-(g)           -
N
N
CH3
CH3
O
MeOOC
O
CH3
H
H
H
H
H
ab
c
d
e
f
g
h
i
j
k
l
m
n
o
p
a'
b'
c'd'
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EXPANDED AROMATIC REGION
MASS SPECTRAL STUDIES OF METHYL-4-(4-METHOXYPHENYL)-6-[6-
M E T H Y L - 2 - ( 4 - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 -
YL]CYCLOHEX-2-ONE-3-ENE-1-CARBOXYLATE
N
N
CH3
CH3
O
MeOOC
O
CH3
H
H
H
H
H
m/z = 480
N
N
CH3
CH3
O
MeOOC
O
CH3
H
H
H
H
H
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N
N
CH3
CH3
O
MeOOC
OCH3
m/z = 480
N
N
CH3
CH3
O
O
CH3
m/z = 421
N
N
CH3
CH3
O
m/z = 313
N
N
CH3
CH3
O
MeOOC
m/z = 447
O
MeOOC O
CH3
m/z = 258
N
N
CH3
CH3
m/z = 222
N
N
CH3
CH3
CH
m/z = 247
N
N
CH3
CH3
m/z = 92m/z = 131
H3CO
m/z = 107
HC
CH
CH3
m/z = 65
MASS FRAGMENTATION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF METHYL-4-ARYL-6-[6-
M E T H Y L - 2 - ( 4 - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 -
YL]CYCLOHEX-2-ONE-3-ENE-1-CARBOXYLATES
[A] Synthesis of  6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine :
See (A), part-I, section-I (A), page no.046.
[B]    Synthesis of 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde:
See (A), part-I, section-I (B), page no.046.
[C] Synthesis  of 1-(4-Methoxyphenyl)-3-[6-methyl-2-(4-methylphenyl)
imidazo [1,2-a] pyridin-3-yl]prop-2-ene-1-one :
See (A), part-I, section-I (C), page no.047.
[D] Synthesisof Methyl-4-(4-methoxyphenyl)-6-[6-methyl-2-(4-methylphenyl)
imidazo[1,2-a]pyridin-3-yl]cyclohex-2-one-3-ene-1-carboxylate :
A mixture of 1-(4-Methoxyphenyl)-3-[6-methyl-2-(4-methylphenyl) imidazo [1,2-
a] pyridin-3-yl]prop-2-ene-1-one3.82gm (0.01mol), methyl acetoacetate 1.3 gm( 0.01
mol) and dry K2CO3 2.76gm (0.02 mole) was taken in 40 ml dry acetone.The reaction
mixture refluxed for 8 hrs. Allowed to stand for over night at room temperature and
filtered it and washed with water. Dryed it and recrystallized from ethanol. Yield 65%,
m.p.dec. 205 oC. Elemental Analysis Calcd. for C30H28N2O4 requires : C-74.98%, H-
5.87%, N-5.83, found : C-75.08%, H-5.80%, N-5.67%.
Similarly, other Methyl-4-aryl-6-[6-methyl-2-(4-methylphenyl)imidazo[1,2-
a]pyridin-3-yl]cyclohex-2-one-3-ene-1-carboxylates were prepared. The physical data
are recorded in table no.04.
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[E] Biological screening of Methyl-4-aryl-6-[6-methyl-2-(4-methylphenyl)
imidazo[1,2-a]pyridin-3-yl]cyclohex-2-one-3-ene-1-carboxylates :
Antimicrobial testing was carried out as described in (A), part-I, section-I, (E),
page no.047. The zones of inhibition of test solutions are reported in graphical chart
no.04.
Conclusion :
Antibacterial activity
The screening data indicated that among cyclohexenone derivatives tested
compounds 4b, 4l showed greater degree of antibacterial activity against S.aureus.
However, the compounds 4b, 4c, 4e, 4h, 4j, 4k showed greater degree of antibacterial
activity against B.subtilis. The compounds 4d, 4k, 4l showed greater degree of
antibacterial activity against E.coli  and no any compounds showed greater degree of
antibacterial activity against  P. aeruginosa.
Antifungal activity
The screening data indicated that among cyclohexenone derivatives tested
compounds 4a, 4c, 4k showed greater degree of antifungal activity against A.niger.
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SECTION-II
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-4-(4-METHOXY
PHENYL)-6-[6-METHYL-2-(4-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-
YL]CYCLOHEX-2-ONE-3-ENE-1-CARBOXYLATES
Cyclohaxenone derivatives play important role to their wide range of biological
activities. Looking to the interesting properties, we have synthesized a series of
cyclohexenone of type-(V) for obtaining biologically potent agents, which were prepared
by reacting 1-Aryl-3-[6-methyl-2-(4-methylphenyl) imidazo [1,2-a] pyridin-3-yl]prop-
2-ene-1-ones of type-(I) with ethyl acetoacetate in acetone media in presence of basic
catalyst like dry K2CO3.
    
N
N
O
CH3
CH3
R
N
N
CH3
CH3
O
R
EtOOCEAA
K2CO3
The structure elucidation of synthesized compounds have been characterized by
using elemental analysis, IR spectra, 1H NMR spectroscopy and further supported by
Mass spectrometry.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg. The
biological activities of synthesized compounds were compared with standard drugs.
The details have been cited in (A), part-I, section-I(E), page no.047.
 Type-(I)                         R=Aryl                    Type-(V)
                                  Cyclohexenone...
085Studies on some compounds....
IR SPECTRAL STUDIES OF  ETHYL-4-(4-METHOXYPHENYL)-6-[6-METHYL-2-
(4-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]CYCLOHEX-2-ONE-3-ENE-1-
CARBOXYLATE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer ;  Frequency range :  4000-400 cm-1 (KBr disc)
  Alkane  C-H str. (asym.) 2963  2975-2950      189
-CH3  C-H str. (sym.) 2856  2880-2860        ,,
 C-H def. (asym.) 1431 1470-1435        ,,
 C-H def. (sym.) 1361 1390-1370        ,,
Aromatic  C-H  str. 3055 3090-3030     190
 C=C str. 1527 1540-1480       ,,
 C-H i.p. (def.) 1122 1125-1090       ,,
 809                   835-810                   ,,
Ethoxy  C-O str. 1242 1260-1200       ,,
Cyclohexne  C=O str. of ester 1732 1750-1725     189
C=O str.of cyclo. 1672 1720-1690       ,,
Imidazo[1,2-a]  C=N str. 1585 1612-1593       ,,
pyridine  C-N str. 1180 1220-1020                 ,,
  Type    Vibration      Frequency in cm
-1    Ref.
     Mode                  Observed               Reported
N
N
CH3
CH3
O
CH3
OO
O
H
HH
H
H
CH3
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NMR SPECTRAL STUDIES OF ETHYL-4-(4-METHOXYPHENYL)-6-[6-METHYL-
2-(4-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]CYCLOHEX-2-ONE-3-ENE-
1-CARBOXYLATE
N
N
CH3
CH3
O
CH3
O
O
O
H
HH
H
HCH3 a
b
c
d
a'b'
c'd'
e
f
g
h
i
j
k
l
m
n
o
p
q
    Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer (200 MHz)
   Signal   Signal Position    Relative No     Multiplicity          Inference            J Value
      No.           (δppm)           of protons                                             In Hz
       1           0.89-0.93      3H    triplet   Alkyl-CH3 (n)                            -
       2  2.37      6H                singlet              Ar-CH3(o-p)  -
       3           2.99-3.28                2H    doublet    Cyclo(k-l)  -
       4  3.83      3H    singlet                Ar-OCH3  -
       5         3.93-3.96      2H    quartet   Alkyl-CH2 (m)   -
       6         4.02-4.09                 1H    doublet     Cyclo(i)             14.0
       7          4.34-4.39      1H    multiplet     Cyclo(h)   -
       8              6.51      1H    singlet     Cyclo(j)   -
       9          6.89-6.93      2H    doublet   Cyclo(a-a’) 8.2
      10          7.04-7.08      1H    doublet     Ar-H (f) 9.2
      11             7.21-7.25      2H   doublet     Ar- (c-c’) 7.6
      12          7.46-7.52      4H   doublet   Ar-(b,b’-d,d’) 8.8
      13              7.56      1H   doublet        Ar-(e)  -
      14              8.00                  1H   singlet       Ar-(g)  -
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EXPANDED AROMATIC REGION
MASS SPECTRAL STUDIES OF ETHYL-4-(4-METHOXYPHENYL)-6-[6-METHYL-
2-(4-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]CYCLOHEX-2-ONE-3-ENE-
1-CARBOXYLATE
m/z = 480
N
N
CH3
CH3
O
CH3
OO
O
H
HH
H
H
CH3
N
N
CH3
CH3
O
CH3
OO
O
H
HH
H
H
CH3
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MASS FRAGMENTATION
N
N
CH3
CH3
O
CH3
O
O
O
CH3
m/z = 494
N
N
CH3
O
CH3
O
OO
CH3
m/z = 403
N
N
CH3
CH3
O
CH3
O
m/z = 421
N
N
CH3
m/z = 130
O
CH3
O
O
O
CH3 m/z = 272
O
m/z = 92
N
N
CH3
CH3
m/z = 222
N
N
CH3
CH3
CHm/z = 247
N
N
CH3
m/z = 206
O
O
O
O
CH3 m/z = 272
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-4-ARYL-6-[6-
M E T H Y L - 2 - ( 4 - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 -
YL]CYCLOHEX-2-ONE-3-ENE-1-CARBOXYLATES
[A] Synthesis of  6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine :
See (A), part-I, section-I(A), page no.046.
[B]    Synthesis of 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde:
See (A), part-I, section-I(B), page no.046.
[C] Synthesis  of 1-(4-Methoxyphenyl)-3-[6-methyl-2-(4-methylphenyl)
imidazo [1,2-a] pyridin-3-yl]prop-2-ene-1-one :
See (A), part-I, section-I(C), page no.047.
[D] Synthesis of Ethyl-4-(4-methoxyphenyl)-6-[6-methyl-2-(4-methylphenyl)
imidazo[1,2-a]pyridin-3-yl]cyclohex-2-one-3-ene-1-carboxylate :
1-(4-Methoxyphenyl)-3-[6-methyl-2-(4-methylphenyl) imidazo [1,2-a] pyridin-
3-yl]prop-2-ene-1-one 3.82gm (0.01mol) was taken in 40 ml acetone and then ethyl
acetoacetate 1.3 gm ( 0.01 mol) and dry K2CO3 2.76gm (0.02 mol) was added. The
mixture was refluxed for 6.0 hrs and allowed to stand for over night at room temperature.
Then it was filtered, washed with water, dried it and recrystallized from ethanol. Yield
55%, m.p.dec.220 oC. Elemental Analysis Calculated for C31H30N2O4 requires :  C-
74.98%, H-5.87%, N-5.83%, found : C-75.08%, H-5.80%, N-5.67%.
Similarly, other Ethyl-4-aryl-6-[6-methyl-2-(4-methylphenyl)imidazo[1,2-
a]pyridin-3-yl]cyclohex-2-one-3-ene-1-carboxylates were prepared. The physical data
are recorded in table no.05.
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[E] Biological screening of Ethyl-4-aryl-6-[6-methyl-2-(4-methylphenyl)imidazo[1,2-
a]pyridin-3-yl]cyclohex-2-one-3-ene-1-carboxylates :
Antimicrobial testing was carried out as described in (A), part-I, section-I(E),
page no.047. The zones of inhibition of test solutions are reported in graphical chart
no.05.
Conclusion :
Antibacterial activity
The screening data indicated that among cyclohexenone derivatives tested
compounds 5h, 5i, 5l showed greater degree of antibacterial activity against S.aureus.
However, the compounds 5b, 5k showed greater degree of antibacterial activity against
B.subtilis. The compounds 5a, 5e, 5g, 5l and 5f, 5i, 5j showed greater degree of
antibacterial activity against E.coli  and P. aeruginosa respectively.
Antifungal activity
The screening data indicated that among cyclohexenone derivatives tested
compounds 5c, 5f showed greater degree of antifungal activity against A.niger.
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091Studies on some compounds....
S 1
  E
th
yl
 ac
et
at
e :
 H
ex
an
e  
(2
 : 8
), 
  S
2 E
th
yl
 ac
et
at
e :
 H
ex
an
e  
(4
 : 6
 )
TA
B
L
E
 - 
05
: P
H
Y
SI
C
A
L 
C
O
N
ST
A
N
T
S 
O
F 
ET
H
Y
L-
4-
A
R
Y
L-
6-
[6
-M
ET
H
Y
L-
2-
(4
-M
ET
H
Y
LP
H
EN
Y
L)
IM
ID
A
ZO
[1
,2
-a
]P
Y
R
ID
IN
-
3-
Y
L]
C
Y
C
LO
H
EX
-2
-O
N
E-
3-
EN
E-
1-
C
A
R
BO
X
Y
LA
TE
S
Sr
.
   
   
 R
   
   
 M
ol
ec
ul
ar
   
   
   
   
   
   
 M
ol
ec
ul
ar
 M
.P
.
    
Y
ie
ld
   
   
 %
 o
f N
itr
og
en
   
   
 R
f
   
 S
ol
ve
nt
N
o
    
    
Fo
rm
ul
a
  W
ei
gh
t
  o
C
   
   
%
    
C
al
cd
.
   F
ou
nd
   
 V
al
ue
   
 S
ys
te
m
 1
   
   
 2
   
   
   
   
 3
   
   
 4
   
 5
   
   
 6
   
   
  7
   
   
   
   
   
 8
   
   
  9
   
   
   
 1
0
 5
a 
   
   
   
C
6H
5-
C
30
H
28
N
2O
3
46
4
19
5
65
 6
.0
3
6.
05
0.
52
   
   
   
S 2
 5
b 
   
   
   
4-
C
l-C
6H
4-
C
30
H
27
C
lN
2O
3
49
8.
5
19
0
76
 5
.6
1
5.
55
0.
51
   
   
   
S 1
 5
c 
   
   
   
2,
4-
(C
l) 2
-C
6H
3-
C
30
H
26
C
l 2N
2O
3
53
3
13
4
78
 5
.2
5
5.
31
0.
49
   
   
   
S 1
 5
d 
   
   
   
4-
N
O
2-C
6H
4-
C
30
H
27
N
3O
5
50
9
17
2
61
  8
.2
5
8.
24
0.
55
   
   
   
S 2
 5
e 
   
   
   
4-
O
C
H
3-C
6H
4-
C
31
H
30
N
2O
4
49
4
de
c.
22
0
55
  5
.6
6
5.
61
0.
60
   
   
   
S 2
 5
f
   
 4
-C
H
3-C
6H
4-
C
31
H
30
N
2O
3
47
8
19
0
60
  5
.8
5
5.
91
0.
40
   
   
   
S 1
 5
g
   
 4
-O
H
-3
-O
C
H
3-C
6H
3-
C
31
H
30
N
2O
5
51
0
13
5
71
  5
.4
9
5.
48
0.
55
   
   
   
S 1
 5
h
   
 4
-B
r-
C
6H
4-
C
30
H
27
B
rN
2O
3
54
3
20
5
76
  5
.1
5
5.
14
0.
48
   
   
   
S 1
 5
i  
   
   
   
2-
O
H
-C
6H
4-
C
30
H
28
N
2O
4
48
0
19
2
45
  5
.8
3
5.
80
0.
46
   
   
   
S 2
 5
j  
   
   
   
4-
O
H
-C
6H
4-
C
30
H
28
N
2O
4
48
0
13
0
51
  5
.8
3
5.
79
0.
44
   
   
   
S 1
 5
k 
   
   
   
4-
N
H
2-C
6H
4-
C
30
H
29
N
3O
3
47
9
17
0
56
  8
.7
6
8.
77
0.
44
   
   
   
S 2
 5
l
   
 2
-C
4H
3S
-
C
28
H
26
N
2O
3S
47
0
20
0
54
  5
.9
5
5.
96
0.
50
   
   
   
S 2
                                  Cyclohexenone...
092Studies on some compounds....
G
ra
ph
ic
al
 C
ha
rt
 N
o.
 0
5 
: A
N
T
IM
IC
R
O
B
IA
L 
A
C
T
IV
IT
Y
 O
F 
ET
H
Y
L-
4-
A
RY
L-
6-
[6
-M
ET
H
Y
L-
2-
(4
-M
ET
H
Y
LP
H
EN
Y
L)
   I
M
ID
A
ZO
[1
,2
-a
]P
Y
R
ID
IN
-3
-Y
L]
C
Y
C
LO
H
EX
-2
-O
N
E-
3-
EN
E-
1-
C
A
R
BO
X
Y
LA
TE
S
05
1
0
1
5
2
0
2
5
3
0
ZONES OF INHIBITION IN mm
S
.a
u
re
u
s
14
12
16
17
14
13
16
21
22
11
14
20
24
24
17
18
0
B
.s
u
b
ti
lis
16
18
15
9
12
11
8
16
10
10
20
14
22
20
17
24
0
E.
co
li
18
17
17
12
21
15
21
15
14
17
21
18
21
21
23
19
0
P
. a
e
ru
g
in
o
s
a
15
9
12
11
8
18
12
17
18
18
14
17
18
22
20
21
0
A
. n
ig
e
r
20
15
18
9
13
22
12
12
16
15
17
15
0
0
0
0
24
5a
5b
5c
5d
5e
5f
5g
5h
5i
5j
5k
5l
A
m
o
xi
ci
lli
n
B
e
n
z
yl
p
e
n
ic
ill
in
C
ip
ro
fl
o
xa
ci
n
Er
yt
h
ro
m
y
ci
n
G
ri
s
e
o
fu
lv
i
n
                                  Cyclohexenone...
093Studies on some compounds....
SECTION-III
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-ACETYL-4-ARYL-6-[6-
M E T H Y L - 2 - ( 4 - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 -
YL]CYCLOHEX-2-ONE-3-ENES
Cyclohexenone derivatives have considerable attention in view of their potential
pharmacological properties such as antimicrobial, anticonvulsant, anticancer, etc. Led
by these considerations, the preparation of cyclohexenone derivatives of type-(VI) has
been undertaken. The synthesis was carried out by the condensation of 1-Aryl-3-[6-
methyl-2-(4-methylphenyl) imidazo [1,2-a] pyridin-3-yl]prop-2-ene-1-ones of type-(I)
with acetyl acetone in the presence of basic catalyst like dry K2CO3  shown as under.
    
N
N
O
CH3
CH3
R
N
N
CH3
CH3
CH3
O
O
R
K2CO3
Acetyl acetone
The structure elucidation of synthesized compounds has been characterized by
using elemental analysis, IR spectra, 1H NMR spectroscopy and further supported by
Mass spectrometry.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg. The
biological activities of synthesized compounds were compared with standard drugs.
The details have been cited in (A), part-I, section-I(E), page no.047.
 Type-(I)                                              Type-(VI)      R=Aryl
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IR SPECTRAL STUDIES OF 1-ACETYL-4-(2,4-DICHLOROPHENYL)-6-[6-
METHYL-2- (4-METHYLPHENYL)IMIDAZO[1 ,2-a ]PYRIDIN-3-YL]
CYCLOHEX-2-ONE-3-ENE
      Instrument : SHIMADZU  FTIR  8400 Spectrophotometer ;  Frequency range :  4000-400 cm-1 (KBr disc)
  Alkane  C-H str. (asym.) 2977  2975-2950      189
-CH3  C-H str. (sym.) 2857  2880-2860        ,,
 C-H def. (asym.) 1406 1470-1435        ,,
 C-H def. (sym.) 1388 1390-1370        ,,
Aromatic  C-H  str. 3085 3090-3030      190
 C=C str. 1500 1540-1480        ,,
 C-H i.p. (def.) 1051 1125-1090        ,,
 790                   790-800                    ,,
Halide  C-Cl str.  605   800-600        ,,
Cyclohex-  C=O str. 1687 1725-1690        ,,
enone  C=O str.of cyclo. 1682 1720-1690        ,,
Imidazo[1,2-a]  C=N str. 1583 1612-1593        ,,
pyridine  C-N str. 1197 1220-1020                  ,,
 Type    Vibration      Frequency in cm
-1    Ref.
     Mode                  Observed               Reported
N
N
CH3
CH3
Cl
O
MeOC
Cl
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NMR SPECTRAL STUDIES OF 1-ACETYL-4-(2,4-DICHLOROPHENYL)-6-[6-
METHYL-2- (4-METHYLPHENYL)IMIDAZO[1 ,2-a ]PYRIDIN-3-YL]
CYCLOHEX-2-ONE-3-ENE
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer (200 MHz)
   Signal    Signal Position    Relative No       Multiplicity           Inference        J Value      No.           (δppm)           of protons                                              In Hz
    1            2.34    3H    singlet                 Ar-CH3(n) -
    2            2.36    3H    singlet                 Ar-CH3(o) -
    3            2.50    3H    singlet    O=C-CH3(p) -
    4       2.73-2.85    2H    doublet               Cyclo(m-l)             -
    5            4.30                1H    doublet      Cyclo(j) -
    6            4.72                1H    multiplet      Cyclo(i)             -
    7       6.99-7.03    1H    singlet      Cyclo(k) -
    8       7.17-7.21                2H    doublet     Ar-H(d-d’)           7.4
    9       7.29-7.34                1H    doublet      Ar-H(g)          11.4
   11               7.54                1H    doublet      Ar-H (f)           8.0
   10            7.48    3H    multiplet     Ar-H(c,e-e’)             -
   12               7.61    1H    singlet       Ar-H (h) -
   13           7.75    2H    doublet       Ar-H (b)           8.8
   14               7.80                1H     singlet       Ar-H (a)           8.0
N
N
CH3
CH3
O
MeOC
H
H
H
H
H
Cl
Cl a
bc
d
e' d'
e
f
g
h i
j
k
l
m
n
o
p
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EXPANDED AROMATIC REGION
MASS SPECTRAL STUDIES OF 1-ACETYL-4-(2,4-DICHLOROPHENYL)-6-[6-
METHYL-2- (4-METHYLPHENYL)IMIDAZO[1 ,2-a ]PYRIDIN-3-YL]
CYCLOHEX-2-ONE-3-ENE
N
N
CH3
CH3
O
MeOC
H
H
H
H
H
Cl
Cl
m/z = 503
N
N
CH3
CH3
Cl
O
MeOC
Cl
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MASS FRAGMENTATION
N
N
CH3
CH3
Cl
O
Cl
CH3
O
m/z = 502
N
N
CH3
CH3
Cl
O
Cl
O
m/z = 487
O Cl
m/z = 203
N
N
CH3
CH3
Cl
O
Cl
m/z = 459
O
Cl
CH3O
m/z = 245
N
N
CH3
CH3
m/z = 222
N
N
m/z = 115
CH2
CH2CH3
m/z = 65 m/z = 77
O Cl
m/z = 95 m/z = 111
                                  Cyclohexenone...
098Studies on some compounds....
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-ACETYL-4-ARYL-6-[6-
M E T H Y L - 2 - ( 4 - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 -
YL]CYCLOHEX-2-ONE-3-ENES
[A] Synthesis of  6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine :
See (A), part-I, section-I(A), page no.046.
[B] Synthesis of 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-
carbaldehyde:
See (A), part-I, section-I(B), page no.046.
[C] Synthesis of 1-(2,4-Dichlorophenyl)3-[6-methyl-2-(4-methylphenyl)
imidazo[1,2-a]pyridin-3-yl]prop-2-ene-1-one :
See (A), part-I, section-I(D), page no.047.
[D] Synthesis  of 1-Acetyl-4-(2,4-dichlorophenyl)-6-[6-methyl-2-(4- methyl
phenyl)imidazo[1,2-a]pyridin-3-yl]cyclohex-2-one-3-ene :
A mixture of 1-(2,4-Dichlorophenyl)-3-[6-methyl-2-(4-methylphenyl) imidazo
[1,2-a]pyridin-3-yl]prop-2-ene-1-one 4.21gm (0.01mol), acetylacetone 1.1gm ( 0.011
mol) and dry K2CO3 2.76gm (0.02 mol) was taken into 40 ml dry acetone. Reaction
mass was refluxed for 10 hrs. Allowed to cool at room temperature for 6 hrs. Separated
solid was filtred and washed with water. Dried it and recrystallized from ethanol. Yield
74%, m.p.dec 200 oC. Elemental Analysis Calculated for C24H18Cl2N2O requires : C-
68.42%, H-4.31%, N-6.65%,  found : C-69.02%, H-4.50%, N-6.57%.
Similarly, other 1-Acetyl-4-aryl-6-[6-methyl-2-(4-methylphenyl)imidazo[1,2-
a]pyridin-3-yl]cyclohex-2-one-3-enes were prepared. The physical data are recorded
in table no.06 .
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[F] Biological screening of 1-Acetyl-4-aryl-6-[6-methyl-2-(4-methylphenyl)
imidazo[1,2-a]pyridin-3-yl]cyclohex-2-one-3-enes :
Antimicrobial testing was carried out as described in (A), part-I, section-I(E),
page no.047. The zones of inhibition of test solutions are reported in graphical chart
no.06.
Conclusion :
Antibacterial activity
The screening data indicated that among cyclohexenone derivatives tested
compounds 6a, 6c, 6d, 6i, 6l showed greater degree of antibacterial activity against
S.aureus. However, the compounds 6c, 6e, 6f, 6g, 6j showed greater degree of
antibacterial activity against B.subtilis. The compounds 6d, 6g, 6i, 6k and 6h showed
greater degree of antibacterial activity against E.coli  and P. aeruginosa respectively.
Antifungal activity
The screening data indicated that among cyclohexenone derivatives tested
compounds 6e showed greater degree of antifungal activity against A.niger.
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STUDIES ON
CYANOPYRIDINES
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INTRODUCTION
Pyridine with different functional groups, exhibit wide range of applications in
the field of pharmaceutical, agriculture and dyes. Although many substituted pyridine
compounds like other heterocyclic compounds are synthesized with their functional group
present in cyclic compounds. The simple pyridine compounds are prepared by the
cyclization of aliphatic raw material. The availability of 3-cyanopyridines, nicotinamide
and nicotinic acid make possible their use as synthetic intermediates.
Most of pyridine derivatives are synthesized by manipulation of pyridine and its
simple homologues in a manner similar to chemistry of the benzenoid chemistry. However
the simple pyridine compounds are prepared by the cyclization of aliphatic raw materials.
In our continuation work in the chemistry of pyridine nucleus, we have undertaken the
synthesis of imidazo[1,2-a]pyridine derivatives.
SYNTHETIC ASPECT
Different methods for the preparation of 3-cyanopyridines are available in
literature.233-239 The well known methods are:
1. Samour and co-workers prepared substituted cyanopyridines by the
condensation of chalcones with ethyl acetoacetate and malanonitrile in
presence of ammonium acetate.240-241
2. Tsutsumi et al.242 have synthesized 3-cyano pyridines by cyclocondensation
of cyanoacetamide with ethyl acetoacetate in the presence of base.
3. Substituted cyanopyridine derivatives were also prepared from 3-substituted
phenyl pyrazolone derivatives with malononitrile.243
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4. Sakuri and Midorikaw244-245 have reported that malononitrile reacts with α,β-
unsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted pyridines(III).
5. Dao-Lin& Kimiaki246 have prepared 2-methoxy -3-cyano pyridine derivatives
by the condensation of α,β- unsaturated ketones with malano nitrile in sodium
methoxide.
               
R R1
O
+
N
N
N R1
RN
O
CH3
MECHANISM
The reaction proceeds through conjugate addition of active methylene compounds
to the α,β-unsaturated system as shown below.
         
R O
R1
HC
CN
CN_
R O
R1
CN
N
CH3COONH4
R O
R1
CN
N
R
R1
CN
NNHN
R1
R NH2
CNH
-
CH3COONH4
-H2O
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THERAPEUTIC IMPORTANCE
Cyanopyridine have attracted considerable attention as they appeared of interest
to possess antibacterial, anticholestemic, antifungal, antihypertensive and antidiabetic
activities. Hammana Abou and co-workers247 have studied anticancer and anti HIV activity
of 3-cyanopyridines. Abdallah Navine et al.248 have prepared cyanopyridine derivatives
which showed analgesic and antiinflammatory activity. Manna Fedele and co-workers249
have reported the antiinflammatory activity of 3-cyanopyridines. Yoshida H.et al.250 have
studied the antihistamic and antiallergic activity of 3-cyanopyridine derivatives. Abd El-
Galil and co-workers251 have prepared 3-cyanopyridines (I) and studied their
pharmacological activity. Gadaginamath and co-workers252 have synthesized various
cyanopyridyl derivatives (II) and documented their variety of biological activities.
      
N
N
N
Ar
NH2 NH2
ArN N
     N NNH2
O
CH3
R
CH3 CH3
O
N
Roman S. V. et al.253 have synthesized 2-amino-3-cyanopyridines and reported
their biological activity. El-Taweel and co-workers254 have prepared cyanopyridine
derivatives and showed their significant biological activity. Parikh A.R.et al.255 have
synthesized 3-cyanopyridine derivatives as antimicrobial agent.
Hussan M. and co-workers256 have prepared 3-cyanopyridines and reported their
pharmacological activity. Pyachenko U. D. et al.257 have synthesized some cyanopyridines
which are useful in the treatment of retroviral disease.
Thiele Kurt et al.258 have studied the analgesic activity of substituted 3-
(I) (II)
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cyanopyridines. N. Latif and co-workers259 have reported the antibacterial and antifungal
activity of 2-amino-3-cyano-4,6-disubstituted pyridines. M. Bernard et al.260 have
reported the anticonvulsant activity of 3-cyanopyridines. D.G. Bhatt et al.261 have
prepared 3-cyanopyridines as an immunosuppressive agent. U. Teu and co-workers262
have shown cyanopyridine as agrochemical fungicides.
Van Allan J. A.et al.263 have prepared fused heterocyclic 3-cyanopyridine (III).
Abu and co-workers264 have prepared novel fused cyanopyridines (IV) for the treatment
and preparation of systemic fungal infection.
            
S N
N
C6H5
NH2
N
           S
N
NH2
CH3
NH2
N
N
Kadlec K. and Hanslian265 showed that 2-methyl-3-nitro-4-methoxyethyl-5-cy-
ano-6-chloro pyridines caused occupational eczema in Vitamin B6. Rigterink and
Raymond266 have studied the pesticidal activity of 3-cyanopyridines. Pavia M.R.et al.267
have prepared N-substituted 2- aminopyridines which possess anticonvulsant property.
3-Cyanopyridines reported by L. Castedo et al.268 showed a minimum inhibitory con-
centration of 1.56 µg/ml against S.aureus.
Baldwin J. J.269-271 have prepared cyanopyridines exhibiting antihypertensive
activity. Streightoff272 and Seydel J.273 have studied the bacteriostatic effect of some
substituted 3-cyanopyridines. Francis and co-workers274 have studied the effect of some
substituted pyridines on the growth of the walker carcinosarcome-256 in tissue culture.
Barton et al.275 have reported fungicidal and insecticidal properties. W. Hoefling and
co-workers276 have studied 3 and 4-cyanopyridines as tuberculosis arresting agents.
(III) (IV)
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W.Von Behenburg and co-workers277 have synthesized 2-amino-3,6- disubstituted
pyridines as antiepileptic agents.
Dipeptidyl peptidase (DPP-IV) inhibition has the potential to become a valuable
therapy for diabetes. Edwin B. Villhauer and co-workers278 have reported the first use
of solid-phase synthesis in the discovery of a new DPP-IV inhibitor class and a solution-
phase synthesis that is practical up to the multikilogram scale. One compound, NVP-
DPP728 (V), is profiled as a potent, selective and shortacting DPP-IV inhibitor that has
excellent oral bioavailability and potent antihyperglycemic activity.
                               
N NH
NH
O
N
CN
NC
Marco J. L. et al.279 have synthesized acetylcholinesterase inhibitors. Moustafa
M. A. et al.280 have prepared antibacterial agents. Eduardo H. S. Sousa et al.281
documented thionicotinamide coordinated to a model system for the in vitro activation
of thioamides antituberculosis drugs. Rosentreter Ulrich et al.282 have synthesized a new
cyanopyridine as receptor agonists in the treatment of cardiac or urogenital disease
cancer, inflammation, neurodegenerative disease(VI). Gary T. Wang and co-workers283
have synthesized o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as
inhibitors of farnesyl transferase(VII).  Abdel-Galil E. Amr and Mohamed M. Abdulla284
have synthesized pyridine derivative (VIII) fused with steroidal structure.
(V)
                                  Cynopyridine...
107Studies on some compounds....
              N
CN
CNR2CH2S
NH2
O(CH2)n OR1
                                                                 
N
O
N
N
NC
N
R1
R2
F3C
CN
CH3
                                 
N
O
CH3
N
CH3
Ar
CH3
CH3
In view of therapeutic activities shown by cyanopyridines, it was contemplated
to synthesise some new cyanopyridines in search of agents possessing higher biological
activity with least side effect have been described as under.
SECTION-I :SYNTHESIS AND BIOLOGICAL SCREENING OF 2-AMINO-6-
ARYL-4-[6-METHYL-2-(4-METHYLPHENYL)IMIDAZO[1,2-
a]PYRIDIN-3-YL]NICOTINONITRILES
(VIII)
(VI)
(VII)
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-AMINO-6-ARYL-4-[6-
M E T H Y L - 2 - ( 4 - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 -
YL]NICOTINONITRILES
 Cyanopyridines play a vital role owing to their range of biological and
physiological activites. In the light of these biological activities and variety of industrial
applications, some new  2-Amino-6-aryl-4-[6-methyl-2-(4-methylphenyl)imidazo[1,2-
a]pyridin-3-yl]nicotinonitriles derivatives of type (VII) have been prepared by the
cyclocondensation of 1-Aryl-3-[6-methyl-2-(4-methylphenyl)imidazo [1,2-a] pyridin-
3-yl]prop-2-ene-1-ones with malononitrile in presence of ammonium acetate.
    
N
N
O
CH3
CH3
R
N
N
N
NH2
CH3
R
CH3
N
CH3COONH4
NCCH2CN
The structure elucidation of synthesized compounds have been
characterized by using elemental analysis, IR spectra, 1H NMR spectroscopy and further
supported by Mass spectrometry.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg. The
biological activities of synthesized compounds were compared with standard drugs.
The details have been cited in (A), part-I, section-I(E), pageno.047.
 Type (I)                  R = Aryl                        Type (VII)
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IR SPECTRAL STUDIES OF 2-AMINO-6-(4-METHOXYPHENYL)-4-[6-ME-
T H Y L - 2 - ( 4 - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 - Y L ]
NICOTINONITRILE
Alkane C-H str. (asym.)         2917                2975-2950              189
-CH3 C-H str. (sym.)           2857                2880-2860  ,,
C-H def.(asym.)         1453                1470-1435  ,,
C-H def. (sym.)         1423                1390-1370  ,,
Aromatic C-Hstr.                      3031                3090-3030              190
C=C str.                    1513                1540-1480  ,,
C-H o.o.p.(def)          800                   800-850  ,,
Amine NH str.                       3372                3400-3300  ,,
Ether C-O-C str.                1206                1260-1200 ,,
Pyridine C=C str.                    1536                1650-1520            189
C=N str.                    1590                1580-1550 ,,
Nitrile           str.                   2257                2240-2120 ,,
Imidazo[1,2-a] C=N str.                    1556                1580-1550              190
pyridine C-N str.                     1039                1220-1020 ,,
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer ;  Frequency range :  4000-400 cm-1 (KBr disc)
C N
Type Vibration                          Ref.
Frequency in cm-1
            
                                             
         Observed           Reported
N
N
N
NH2
CH3
CH3
O
CH3
N
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NMR SPECTRAL STUDIES OF 2-AMINO-6-(4-METHOXYPHENYL)-4-[6-
METHYL-2-(4-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]
NICOTINONITRILE
    Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer (200 MHz)
   Signal    Signal Position    Relative No      Multiplicity           Inference         J Value      No.           (δppm)           of protons                                              In Hz
     1            2.31     3H   singlet      Ar-CH3(i) -
     2            2.34     3H   singlet     Ar-CH3(j)             -
     3            3.31     2H   singlet        NH2(l)                   -
     4            3.91     3H   singlet     Ar-OCH3(k) -
     5            6.92     1H   singlet       pyr- (e) -
     6       7.12-7.16                 2H doublet     Ar-H(a-a’)            9.4
     7       7.21-7.25                 2H  doublet     Ar-H(c-c’)            7.8
     8       7.40-7.44     1H  doublet       Ar-H(g) -
     9           7.55-7.59                 2H  doublet     Ar-H (d-d’)            8.8
    10          7.74-7.78     2H doublet     Ar-H (b-b’)            7.6
    11       7.97-8.00     1H  doublet         Ar-(f) -
    12            8.16     1H  singlet         Ar-(h) -
N
N
N
NH2
CH3
CH3
O
CH3N
ab
cd
e
f
g
h
i
j
k
a'b'
c'd'
l
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EXPANDED AROMATIC REGION
MASS SPECTRAL STUDIES OF 2-AMINO-6-(4-METHOXYPHENYL)-4-
[6-METHYL-2-(4-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]
NICOTINONITRILE
m/z = 445
N
N
N
NH2
CH3
CH3
O
CH3
N
N
N
N
NH2
CH3
CH3
O
CH3
N
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MASS FRAGMENTATION
N
N
N
NH2
N
CH3
CH3
O
CH3
m/z = 445
N
N
N
NH2
N
CH3
CH3
m/z = 415
N
N
N
NH2
N
CH3
CH3
m/z = 338
N
N
N
N
CH3
CH3
OCH3m/z = 430
N
N
CH3N
CH3
CH3
m/z = 284
CH3
m/z = 92
N
N
CH3
m/z = 130
N
N
CH3
CH3
m/z = 222
HC
CH
CH3
m/z = 65
N
NH2
N O
CH3
m/z = 225
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-AMINO-6-ARYL-4-[6-
M E T H Y L - 2 - ( 4 - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 -
YL]NICOTINONITRILES
[A] Synthesis of  6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine :
See(A), part-I, section-I(A), page no.046.
[B]    Synthesis of 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde:
See(A), part-I, section-I(B), page no.046.
[C] Synthesis  of 1-(4-Methoxyphenyl)-3-[6-methyl-2-(4-methylphenyl)
imidazo [1,2-a] pyridin-3-yl]prop-2-ene-1-one :
See(A), part-I, section-I(C), page no.047.
[D] Synthesis of 2-Amino-6-(4-methoxyphenyl)-4-[6-methyl-2-(4-methyl
phenyl)imidazo[1,2-a]pyridin-3-yl]nicotinonitrile :
A mixture of 1-(4-Methoxyphenyl)-3-[6-methyl-2-(4-methylphenyl)imidazo [1,2-
a] pyridin-3-yl]prop-2-ene-1-one 3.82gm (0.01mol), malononitrile 0.66 gm (0.01 mol)
and ammonium acetate 6.16gm (0.08 mol) dissolved in methanol was refluxed for 12
hrs. The reaction mixture was poured into crushed ice and kept overnight. Solid separated
was filtered and recrystallized from ethanol. Yield, 68%, m.p. 245oC. Elemental Analysis
Calculated for C28H23N5O ; Requires : C-75.49%, H-5.20%, N-15.72 %; Found : C-
75.41%, H-5.15, N-15.73%.
Similarly, other 2-Amino-6-aryl-4-[6-methyl-2-(4-methylphenyl)imidazo[1,2-
a]pyridin-3-yl]nicotinonitriles were synthesized. The physical data are recorded in table
no.07.
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[E] Antimicrobial activity of 2-Amino-6-aryl-4-[6-methyl-2-(4-methyl phenyl)
imidazo[1,2-a]pyridin-3-yl]nicotinonitriles :
Antimicrobial testing was carried out as described in (A), part-I, section-I(E),
page no.047. The zones of inhibition of the test solutions are recorded in graphical chart
no.07.
Conclusion :
Antibacterial activity
The screening data indicated that among cyanopyridine derivatives tested
compounds 7f, 7j, 7l showed greater degree of antibacterial activity against S.aureus.
However, the compounds 7k showed greater degree of antibacterial activity against
B.subtilis. The compounds 7a, 7g and 7c, 7h, 7j showed greater degree of antibacterial
activity against E.coli  and P. aeruginosa respectively.
Antifungal activity
The screening data indicated that among cyanopyridine derivatives tested
compounds 7c, 7d, 7k showed greater degree of antifungal activity against A.niger.
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    PART - IV
STUDIES ON ARYL
AMINOMETHYL DERIVATIVES
                            Aryl amino methyl...
117Studies on some compounds....
INTRODUCTION
In recent years, interest has also focused on aza-analogs such as azomethine de-
rivatives which show a very similar pharmacological profile. Over the past few years,
several compounds have been developed. Azomethines are also known as schiff’s bases
and they are well known intermediates for the preparation of azetidinones, thiazolidinone,
formazan, arylacetamide and many other entities of pharamaceutical potential. These are
the compounds containing characteristic  –HC=N– group.
Azomethines are obtained mainly by warming the aldehyde & aromatic amine
togather. Howeve, it is more convenient to work in a solvent such as alcohol, dilute
acetic acid or glacial acetic acid. Some time the reaction is aided by trace of acid in
other cases the hydrochloride of the amines can be used in the synthesis. In general
Schiff’s bases do not react further with either of  the reagents used in their preparation.
Synthetic Schiff’s base derivatives contribute  in huge libraries owing to their wide appli-
cability in different fields.
SYNTHETIC ASPECT
Different methods for the preparation of azomethine derivatives documented in
literature are described as under.
1. A new one pot procedure for the generation of azomethine via chlorominium
salt has been investigated by Rosaleen J. Anderson and co-workers.285
                   N
O
R2
O
CH
3
O
R1 N
+
O
R
2
O
CH
3
Cl
R
1
COCl2
(I)
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2. General account of the summary of reaction of aldehydes with amine
(aromatic or aliphatic) has been reviewed by Murray. 286
R-CHO R'-NH R-CH=N-R'
2
+
3. Strache287 and VanAlphen 288 have prepared imine involves in two steps.
a. Reaction of amine and aldehyde gives aldol.Which is rarely capable of isolation.
R-CHO R'-NH2+
R-CHOHNHR'
b. The loss of water to give an imine (azomethine), this corresponds to the
“crotonaldehyde stage” of the aldol condensation.
R-CH=N-R'R-CHOHNHR' + H
2
O
4. Oddo & Tognacchini 289 have introduced the comparative rates of formation of
Schiff ‘s base from aromatic amine and aromatic aldehyde using a cryscopic method
follow the course of reaction.
Pierre L. Beaulieu and co-workers 290 have synthesized (E)-N-phenyl
methylene glycine ethyl ester by the cyclocondensation of glycine ethyl ester
hydrochloride, t-butylmethyl ether (TBME), benzaldehyde was added followed by
anhydrous Na
2
SO
4
and triethylamine.
Amanda J. Gallant et al. 291 have prepared schiff ’s bases by condensation of equimolar
quantity of 3,6 diformyl catechol and substituted o-phenylenediamine.
NH
COOEt
2
PhCHO Et N
Na SO
3
TBME2 4
HCl.
48hrs N COOEt
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O OH
OH
N
NH
2
OR
OR
O OH
OH
O
+
NH
2
NH
2
OR
OR
THERAPEUTIC IMPORTANCE
Literature survey reveals that various azomethines have resulted in many potential
drugs and are known to possess broad spectrum of biological activites.
1. Antiviral292
2. Antifungal293
3. Antiparasitic294
4. Antibacterial295
5. Antipyretic296
6. Anti-inflammatory297
7. Plant hormone activity298
8. Antitubercular299
Smalders et al.300 synthesized some new azomethine as potential antitumor agents.
Sharaf El-Din and Nabaweya301 have synthesized some azomethine derivatives (I) having
good antibacterial activity. Chohan et al.302 have synthesized azomethines, which have
been screened and compared for their antibacterial action against bacterial  species
Escherichia coli, Pesudomonas aeruginose and Klebisella  pneumoniasa.
                                           
N
CH
3
OH
R
(I)
R  =   3,4 -OH,  3,4-NO
2
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Schiff’s  bases exhibit a wide range of pharmacological activities like antifungal,
antibacterial, antiviral, anti-inflammatory, etc. Mehta R. H. et al.303 have synthesized
coummarin schiff’s base derivatives (II) and examined for their antibacterial activity.
Khalafallah A. K. and Hassan M. E.304 have prepared some styryl Schiff’s bases spiro
derivatives as potential antibacterial and antifungal activity.
                                      
O O
NH
Deshmukh M. D. and Doshi  A.G.305 prepared some new  Schiff’s bases show
good antimicrobial activity against test organism  S.aureus, E. coli, Saigella dysenteridse
and Salmonella typhi. Wang et al.306 have synthesized diazomethines having good plant
hormone activity. Das Arima et al.307 have prepared Schiff’s bases of  aminohydroxy
guanidine (SB-AHG5) and tested  for antiviral  activity against Herpes Simplex virus
type I (HSV-1) and adenovirus type-5 (Ad-5).
Sabrina Castellano et. al.308 have prepared azomethine derivatives and evaluated
in vitro against several pathogenic fungi responsible for human disease. B. Shivarama
Holla et. al.309 have documented antibacterial, antifungal and herbicidal activity of
azomethine derivatives.Wang, Yangang and co-workers310 have screened some
azomethines having good plant homone activity. Pascal Rathelst et. al.311have reported
some new azomethines as antiparasitic agents.
B.Shivarama Holla., et al.312 have synthesized azomethines of type (III) having
antibacterial and anti-inflammatory activity. Dimmock J. et. al.313 have reported
azomethines as cytotoxic agents.
(II)
                            Aryl amino methyl...
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N
S
NH
N
O
Cl
Cl
Cl
R
Iana Vazzana et. al.314 have synthesised derivatives (IV) and reported them as
anti-inflammatory agents. Neslihan and Reyhan315 have synthesised azomethines and
studied their antitumor activity. R. S. Varma316  has been synthesised a series of new
azomethines.
        
N
N
R
Recently, Parumal P. Selvam and co-workers317 have synthesised azomethine
derivatives and reported their antimicrobial activity. Zhanyong Guo et.al.318-319 have
synthesised schiff’s base of carboxymethyl chitosan and reported their in vitro antifungal
and antioxident activity. Sham M. Sondhi et. al.320 have synthesised azomethine
derivatives(IV) and documented their anti-inflammatory, analgesic and kinase (CDK-1,
CDK-5, and GSK-3) inhibition activity.
         
OH
N
NH
2
NH
2
N
OH
(IV)
(V)
 (III)         R = 2-NO
2
, 4-NO
2
, 4-Br,.....etc.
R = 3-CF
3
, 4-SO
2
NH
2
, 4-SO
2
CH
3
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Jayendra Patole et. al.321 have reported schiff’s base (VI) conjugates of p-Amino
salicyclic acid containing hydroxyl-rich side chains show enhanced antimycobacterial
activity against mycobacterium smegmatis and mycobaterium bovis BCG. Alaaddin
Cukurovali et. al.322 have designed and synthesized azomethine derivatives and investigated
their antibacterial and antifungal activity. Anti-HIV ativity of schiff’s base have reported
by Dharmarajan and co-workers.323
                                               
N
OH
OH
OH
O
Thus with an effort to capitalize the biological potential of the heterocyclic system
and to provide more interesting compounds for biological study, we have undertaken the
synthesis of azomethines bearing imidazo pyridine nucleous.
SECTION-I :   S Y N T H E S I S  A N D  B I O L O G I C A L SCREENING O F N-
     ARYL-1-[6-METHYL-2-(4-METHYLPHENYL)IMIDAZO[1,2-a]
     PYRIDIN-3-YL]METHANIMINES
SECTION-II :SYNTHESIS AND BIOLOGICAL SCREENING OF N-ARYL-1-
                       [6-METHYL-2-(4-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-
   3-YL]METHANAMINES
(VII)
                            Aryl aminomethyl...
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  SECTION-I
S Y N T H E S I S  A N D  B I O L O G I C A L S C R E E N I N G O F N - A RY L - 1 - [ 6 -
M E T H Y L - 2 - ( 4 - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 -
Y L ] M E T H A N I M I N E S
Looking to the interesting properties of azomethines, with an intension to
synthesising better therapeutic agents, azomethine derivatives of type (VIII) have been
synthesized by the condensation of 2-(4-Methylephenyl)imidazo[1,2-a]pyridin-3-
carbaldehyde with different aromatic amines in order to study their biodynamic behaviour.
   
N
N
CH3
CH3
O
N
N
N
CH3
CH3
R
R-NH2
gla.aceticacid
The structure elucidation of synthesized compounds have been characterized by
using elemental analysis, IR spectra, 1H NMR spectroscopy and further supported by
Mass spectrometry.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg. The biological
activities of synthesized compounds were compared with standard drugs. The details
have been cited in(A), part-I, section-I(E), page no.047.
  (VIII)         R = Aryl
                            Aryl aminomethyl...
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IR SPECTRAL STUDIES OF N-(4-METHOXYPHENYL)-1-[6-METHYL-2-(4-
METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHANIMINE
   Instrument : SHIMADZU  FTIR  8400 Spectrophotometer ;  Frequency range :  4000-400 cm-1 (KBr disc)
           
Type
        Vibration Frequency in cm-1                   
   Ref.
                       mode     observed         Reported
      Alkane   C-H str. (asym.)                 2958        2975-2950  189
  -CH3          C-H str. (sym.)             2852             2880-2860             ,,
                     C-H def. (asym.)             1444             1470-1435   ,,
         C-H def. (sym.)             1398             1390-1370   ,,
 AromaticC-H  str.       C-H str.             3026             3090-3030 190
        C=C str.             1481             1540-1480   ,,
         C-H i.p. (def.)             1107             1125-1090   ,,
            1029             1070-1000             ,,
             829             835-810                 ,,
 Imidazo[1,2-a]         C=N str.             1585             1612-1593 189
 pyridine         C-N str.             1244             1220-1020   ,,
    Schiff’s base               C=N str.         1608         1660-1580            ,,
N
N
CH3
CH3
N
O CH3
H
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NMR SPECTRAL STUDIES OF N-(4-METHOXYPHENYL)-1-[6-METHYL-2-(4-
METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHANIMINE
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer (200 MHz)
 Signal    Signal Position   Relative No     Multiplicity         Inference            J Value   No.            (δppm)          of protons                                                       In Hz
   1              2.43   6H       singlet       Ar-CH3(i-j)       -
   2             3.82   3H       singlet       Ar-OCH3(k)           -
   3         6.90-6.95   2H       doublet        Ar-H(a-a’)           8.6
   4         7.19-7.23   2H       doublet       Ar-H(b-b’)      8.8
   5            7.25   2H       doublet        Ar-H(c-c’)      7.0
   6         7.29-7.32   2H       doublet        Ar-H(f-e)              6.6
   7             7.62   1H       singlet          Ar-H(g)        -
   8         7.65-7.69   2H       doublet        Ar-H(d-d’)      7.8
   9             8.78   1H       singlet       Ar-N=CH-(h)           -
N
N
CH3
CH3
N
O CH3
H
a
b a'
b'
c
c'
d
d'e
f
g h
i
j
k
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EXPANDED AROMATIC REGION
MASS SPECTRAL STUDIES OF  N-(4-METHOXYPHENYL)-1-[6-METHYL-
2-(4-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHANIMINE
N
N
CH3
CH3
N
O CH3
H
m/z = 355
N
N
CH3
CH3
N
O CH3
H
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MASS FRAGMENTATION
N
N
CH3
CH3
N
O CH3
m/z = 354
N
N
CH3
CH3
N
O
m/z = 340 N
N
CH3
CH3
N m/z = 324
N
N
CH3
CH3
N m/z = 247
CH
N
m/z = 103
N
N
CH3
CH3
m/z = 222
CH3
HC
CH3
CH
m/z = 92 m/z = 65
CHCH3
C
m/z = 77
CHCH3
CH
m/z = 51
N
N
CH3
m/z = 205
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EXPERIMENTAL
S Y N T H E S I S  A N D  B I O L O G I C A L S C R E E N I N G O F ( E ) - N - A RY L - 1 -
[ 6 - M E T H Y L - 2 - ( 4 - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 -
Y L ] M E T H A N I M I N E S
[A] Synthesis of  6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine :
See(A), part-I, section-I(A), page no.046.
[B] Synthesis of 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-
carbaldehyde :
See(A), part-I, section-I(B), page no.046.
[C] Preparation of N-(4-Methoxyphenyl)-1-[6-methyl-2-(4-methylphenyl)
imidazo[1,2-a]pyridin-3-yl]methanimine :
A mixture of  6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde
2.5g (0.01mol), p-anisidine 1.23g (0.01mol) and catalytic amount of glacial acetic acid
in 20 ml methanol was refluxed for 16hrs. The contents was cooled and product isolated
by filtration and dryed it. The crude product was recrystallized from methanol. Yield,
75%, m.p. 178 oC, Elemental Analysis Calculated for C23H21N3O ; Found : C-77.93%,
H-5.66%, N-11.75%; Requires : C-77.72%, H-5.96%, N-11.82%.
Similarly, N-Aryl-1-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-
yl]methanimines have been prepared. The physical data are recorded in table no.08.
[D] Biological screening of N-Aryl-1-[6-methyl-2-(4-methylphenyl)imidazo
[1,2-a]pyridin-3-yl]methanimines :
Antimicrobial testing was carried out as described in (A), part-I, section-I(E),
pageno.047. The zones of inhibition of test solutions are reported in graphical chart no.08.
                            Aryl aminomethyl...
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Conclusion :
Antibacterial activity
The screening data indicated that among Schiff’s base derivatives tested
compounds 8d, 8k showed greater degree of antibacterial activity against S.aureus.
However, the compounds 8a, 8b, 8e, 8j, 8k showed greater degree of antibacterial
activity against B.subtilis. The compounds 8i, 8k, 8l and 8f, 8g, 8h, 8l showed greater
degree of antibacterial activity against E.coli  and P. aeruginosa respectively.
Antifungal activity
The screening data indicated that among Schiff’s derivatives tested compounds
8c showed greater degree of antifungal activity against A.niger.
                            Aryl aminomethyl...
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   SECTION-II
SYNTHESIS AND BIOLOGICAL SCREENING OF N-ARYL-1-[6-METHYL-2-
(4-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHANAMINES
Aminomethyl derivatives of heterocyclic compounds are associated with diverse
biological activities. These finding prompted us to synthesize some representative
aminomethyl derivative of type (IX) bearing imidazo[1,2-a]pyridine moiety obtained by
selective reduction of schiff’s bases(imine group) of  type (VIII) with sodium borohydride
in controlled experimental condition as shown in the reaction scheme.
   
NaBH4
N
N
N
CH3
CH3
R
N
N
NH
CH3
CH3
R
The structure elucidation of synthesized compounds have been characterized by
using elemental analysis, IR spectra, 1H NMR spectroscopy and further supported by
Mass spectrometry.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg. The biological
activities of synthesized compounds were compared with standard drugs. The details
have been cited in(A), part-I, section-I(E), page no.047.
       Type (VIII)                                           Type (IX)               R = Aryl
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IR SPECTRAL STUDIES OF N-(4-METHOXYPHENYL)-1-[6-METHYL-2-(4-
METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHANAMINE
 Instrument : SHIMADZU  FTIR  8400 Spectrophotometer ;  Frequency range :  4000-400 cm-1 (KBrdisc)
          
   Type
        Vibration Frequency in cm-1                    
 Ref.
                       mode     observed         Reported
     Alkane  C-H str. (asym.)                  2942        2975-2950 189
-CH3        C-H str. (sym.)             2899             2880-2860             ,,
                   C-H def. (asym.)             1463             1470-1435   ,,
       C-H def. (sym.)             1388             1390-1370   ,,
 AromaticC-H  str.     C-H str.             3020             3090-3030 190
       C=C str.             1512             1540-1480   ,,
       C-H i.p. (def.)             1114             1125-1090   ,,
            1035             1070-1000             ,,
             823             835-810                 ,,
 Imidazo[1,2-a]      C=N str.             1604             1612-1593 190
 pyridine      C-N str.             1232             1220-1020   ,,
 Amine       N-H str.             3288             3400-3200   ,,
N
N
CH3
CH3
NH
O CH3
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NMR SPECTRAL STUDIES OF N-(4-METHOXYPHENYL)-1-[6-METHYL-2-(4-
METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHANAMINE
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer (200 MHz)
 Signal    Signal Position   Relative No     Multiplicity          Inference            J Value   No.            (δppm)           of protons                                           In Hz
   1             2.31   3H      singlet        Ar-CH3(i)       -
   2       2.33   3H      singlet        Ar-CH3(j)       -
   3             3.64   3H      singlet       Ar-OCH3(k)           -
   4       4.52   2H             singlet       Ar-N-CH2-(h)       -
   5       5.70   1H     singlet          Ar-NH                 -
   6         6.60-6.65   2H     doublet        Ar-H(b-b’)           8.4
   7         6.70-6.75   2H     doublet        Ar-H(a-a’)      8.4
   8   7.13-7.18   2H     doublet          Ar-H(f)              9.0
   9         7.24-7.28   2H     doublet        Ar-H(c-c’)      7.6
  10   7.50-7.55   1H     doublet         Ar-H(e)               9.0
  11         7.65-7.68   2H     doublet        Ar-H(d-d’)      7.6
  12           8.15   1H     singlet          Ar-(g)                  -
N
N
CH3
CH3
NH
O CH3
a
b a'
b'
c
c'
d
d'e
f
g h
i
j
k
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EXPANDED AROMATIC REGION
MASS SPECTRAL STUDIES OF N-(4-METHOXYPHENYL)-1-[6-METHYL-
2-(4-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHANAMINE
N
N
CH3
CH3
NH
O CH3
m/z = 357
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MASS FRAGMENTATION
N
N
CH3
CH3
NH
O CH3
m/z = 357
N
N
CH3
CH3
HN
m/z = 252
N
N
CH3
NH
CH
HC
m/z = 272
N
N
CH3
CH3
CH m/z = 235
N
N
CH3
CH m/z = 219
O CH3
m/z = 108
N
N
m/z = 115 m/z = 77
N
N
CH3
CH
m/z = 142
CH2
CH3
CH3
m/z = 53
NH
CH3
m/z = 92
CH2
CH2CH3
m/z = 65
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF N-ARYL-1-[6-METHYL-2-
(4-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHANAMINES
[A] Synthesis of  6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine :
For preparation see(A), part-I, section-I(A), page no.046.
[B]     Synthesis of 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-
carbaldehyde :
For preparation see(A), part-I, section-I(B), page no.046.
[C] Preparation of N-(4-Methoxyphenyl)-1-[6-methyl-2-(4-methylphenyl)
imidazo[1,2-a]pyridin-3-yl]methanimine :
For preparation see, part-IV, section-I(C), page no.128.
[C] Synthesis of N-(4-Methoxyphenyl)-1-[6-methyl-2-(4-methylphenyl)imidazo
[1,2-a]pyridin-3-yl]methanamine :
3.55g (0.01mol) N-(4-Methoxyphenyl)-1-[6-methyl-2-(4-methylphenyl)imidazo
[1,2-a]pyridin-3-yl]methanimine was taken in 25ml methanol and cooled at 5-10 oC
temperature. Sodium borohydride 0.57g (0.15mol) was added over a period of  30 min.
The reaction mixture stirred over night at room temperature. Reaction mass was then
poured in ice water and  excess borohydride was neutralized by adding dil HCl. The
product was extracted with ether and washed with water. Dried over anhydrous Na2SO4
and finally  the ether  was evaportated  to give aminomethyl derivatives.  Yield, 56%,
m.p. 165 oC, Elemental analysis calculated for C28H23N5O; Found : C- 77.98%; H-
6.48%; N-11.99%; Requires : C-77.28%, H-6.49%, N-11.76%.
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Similarly, other N-Aryl-1-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-
3-yl]methanamines were prepared. The physical data are recorded in table no.09.
[E] Biological screening of N-Aryl-1-[6-methyl-2-(4-methylphenyl)imidazo[1,2-
a]pyridin-3-yl]methanamines :
Antimicrobial testing was carried out as described in (A), part-I, section-I(E),
page no.047. The zones of inhibition of test solutions are reported in graphical chart
no.09.
Conclusion :
Antibacterial activity
The screening data indicated that among arylaminomethyl derivatives tested
compounds 9b, 9d, 9f showed greater degree of antibacterial activity against S.aureus.
However, the compounds 9e, 9i, 9j, 9l showed greater degree of antibacterial activity
against B.subtilis. The compounds 9b, 9d, 9k and 9a, 9f, 9h, 9l showed greater degree
of antibacterial activity against E.coli  and P. aeruginosa respectively.
Antifungal activity
The screening data indicated that among arylaminomethyl derivatives tested
compounds 9c showed greater degree of antifungal activity against A.niger.
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INTRODUCTION
O rganic compounds containing six-membered aromatic  heterocycl ic
rings are widely distributed in nature and often play an important role in various
biochemical processes. Heteroaromatic rings also serve as bioisosters of several sub-
stituents including phenyl rings or carboxylic amide and often render greater  pharmaco-
logical activity to the resulting compounds. As a result, they are commonly incor-
porated into new chemical entities by medicinal chemists.  In some instances, how-
ever, these rings can serve as alternative sites for metabolic attack  and at times may
have the potential of undergoing unusual metabolic transformations that can  result in
toxic events.
Pyrimidine was first isolated by Gabriel and Colman in 1899. Despite the impor-
tance of dihydroazines (particularly those containing the 1,4-dihydropyrimidine and dihy
dropyridine moiety324) for clarifying a wide range of theoretical, medicinal and biologi-
cal problems, the chemistry of this group of compounds is still extremely spotty.325-329
Structure-metabolism relationship (SMR) studies often reveal that incorporation
of one or more heteroatoms in an aromatic ring influences the chemical and biochemical
reactivity of  these compounds and therefore alter their metabolism. Recently, the interest
in the synthesis of these derivatives has increased tremendously because they exhibit
promising activities as calcium-channel modulators, antihypertensive agents, a-1  receptor
antagonists and neuropeptideY (NPY) antagonists330-331 as an anticancer drug capable
of inhibiting Kinesinmotor protein,332 recently, interest has shifted from DHPM calcium
channel modulators to other biologically active DHPM derivatives e.g. α−1 adreno
ceptorselective antagonists, useful for the treatment of benign prostatic hyperplasia.333
Figure (I) depicts the five possible isomeric structures of dihydropyrimidines,
exhibiting different dispositions of the double bonds.
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The synthetic strategies for the dihydropyrimidine nucleus involves one-pot to
multi step approaches. In 1893, the Italian chemist Pietro Biginelli discovered a
multicomponent reaction that produced these multifunctionalized dihydropyrimidinones.
certainly ranks as one of the most recognized and often used MCR’s for the generation
of novel pyrimidine scaffolds.334-336
SYNTHETIC ASPECT
1.      Biginelli reaction337 (1893).
   
CH3
H5C2O
O
O
+
NH2 NH2
O
+
CHO
NH
N
H
OCH3
O
H5C2O
2.      Shingare M. S. et al.338 examined a simple but effective procedure for
Biginelli condensation reaction of an aldehyde, β-ketoester and urea or thio
urea using catalytic amount of cadmium chloride.
     
O
O
O
R1
CH3
+
O
R
H
NH2
NH2
X
CdCI2
EtOH 
NH
N
H
XCH3
O
O
R1
R
+
(I)
X = O, S
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3.       A novel one-pot condensation of an aldehyde,β-keto-ester and urea
wasperformed using iodotrimethylsilane in acetonitrile for the first time
at room temperature affording DHPMs.339
4.       Reddy et al.340 described practical route for the Biginelli reaction using
zirconiumtetrachloride as a catalyst. Three component condensation reaction of an
aromaticaldehyde, β-ketoester and urea or thiourea in ethanol afforded the cor
responding DHPM-2-(1H)-ones in high yield.
5.     Zhang X et al .
341
developed a novel series of 4-substituted 3,4-
dihydropyrimidine2(1H)-thiones employing magnesium perchlorate as an efficient
catalyst under ultrasound irradiation.
           
N
H
NH
S
O
R1O
R2
R3
O
O
O
R2
R3 + +
NH2NH2
S [Mg(ClO4)2]R1 CHO
6.      An important stage in process development is in pilot scale preparation of the
target compound. A procedure involving water-based biphasic media has been
developed for conducting some exothermic reactions on large scale. This protocol
is  rapid preparation of dihydropyrimidinones by a solvent-free, green chemistry
procedure applied to the Biginelli reaction using p-toluensulfonic acid as catalyst.
342
        
CHO
R+
CH3
EtO
O
O
+ NH2NH2
O
NH
N
H
O
EtO
O
CH3
R
p-TSA
H2O
                Dihydropyrimidines...
144Studies on some compounds....
7.     De. S. K. et al.
343
 synthesized novel one pot Biginelli-type reaction. Aromatic
aldehydes with β-dicarbonyl compound and thiourea in presence of catalytic amount
of 5 % of Sc(OTf)3 at 100 
oC .
        
N
H
NH
S
O
RO
R1
R2
O
O
O
R1
R2 + +
NH2NH2
S Sc(OTf)3R CHO
100 
o
C
8.     Abdelmadjid et. al.
344
 synthesized 3,4-dihydropyrimidine derivative was
achieved in good to excellent yields using phenylboronic acid as catalyst to  promote
the Biginelli three-component condensation.
         CH3
O
OEt
O
NH2NH2
O
+ Ar CHO+
Ar
NH
N
H
O
EtO
O
CH3
PhB(OH)2
CH3CN
9.      John Mabry et al.
345
 synthesized different DHPMs via enamine intermediates
using L-proline methyl ester hydrochloride found to be an effective catalyst for
assembling dihydropyrimidine thiones under mild condition.
          N
H
NH
S
R3
R1O
R2O
R2
O
R3
+ +
NH2NH2
S L-proline
R1 CHO
CH3OH
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STEROGENIC CENTER
Dihydropyrimidines of the Biginelli type are inherently asymmetric molecules and
the influence of the absolute configuration at the stereogenic center at C4 on biological
activity is well documented.346
For example, it is exclusively the (R)- enantiomer that carries the therapeutically
desired antihypertensive effect. In other DHPM analogues, individual enantiomers were
demonstrated to have opposing pharmacological activities.347 Access to enatiomerically
pure DHPMs it therefore of considerable interest and a prerequisite for the development
of any drugs in this field (II).
                                      N
N
H
CH3
OO
O
NO2
CH3
CH3
CH3
In the absence of any known general asymmetric synthesis for this heterocyclic
target system, resolution strategies have so far been the method of choice to obtain
enantiomerically pure DHPMs. Optically pure DHPMs were obtained by resolution of
the corresponding racemic-5-carboxylic acids via fractional crystallization of the
corresponding diastereomeric R-methyl benzyl ammonium salts.  The absolute
configuration of acid (S) was proved by single crystal x-ray analysis of a suitable
diastereomeric salt. This method may lead to both enantiomers (R) and (S) figer-(III)
but unfortunately, it is not applicable in general to all DHPMs.
(II)
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(III)
                           N
N
CH3
O
OH
OCH3
CH3
(R) (S)
N
N
CH3
O
OH
OCH3
CH3
Due to recent advances in preparative chromatographic enantioseparation
techniques, enantioselective HPLC and related methods have gained importance in the
synthesis of single enantiomer drugs and intermediates.  In a recent study, the
chromatographic enantioseparation of DHPM derivatives accomplished by using a variety
of commercially available chiral stationary phases (CSPs) in normal and reversed-phase
analytical HPLC is reported.348 Fre'chet and coworkers reported the separation of
DHPMs on a standard Pirkle-type 3,5-dinitrobenzoylated CSP and the "reciprocal"
preparation of DHPM-based CSP.349-350
Thus the important role displayed by DHPMs and its derivatives for various
therapeutic and biological activities prompted us to synthesise some dihydropyrimidinones
and dihydropyrimidinethiones in order to get compounds having better biological activities
as described in the following parts.
PART-I    : STUDIES ON DIHYDROPYRIMIDINONES
PART-II   : STUDIES ON DIHYDROPYRIMIDINETHIONES
    PART - I
STUDIES ON
DIHYDROPYRIMIDINONES
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INTRODUCTION
In recent  years ,  interest  has also focused on aza-analogs such as
dihydropyrimidines (DHPMs) which show a very similar pharmacological profile to clas-
sical dihydropyrimidine calcium channel modulators. 351-354 Over the past few years, sev-
eral lead compounds have been developed355 and claimed to be superior in potency and
duration of antihypertensive activity to classical DHP drugs and compare favorably
with second generation analogues such as amlodipine and nicardipine.356
Pyrimidine is the most important member of all the diazines as this ring system
occurs widely in living organisms. Purines, uric acid, barbituric acid and anti-malarial
and anti-bacterial agents also contain the pyrimidine ring. The chemistry of pyrimidine
has been widely studied. Pyrimidine was first isolated by Gabriel and Colman in 1899.
These inherently asymmetric dihydropyrimidine (DHPM) derivatives are not only
very potent calcium channel modulators, but also have been studied extensively to expand
the existing structure activity relationships and to get further insight into molecular
interactions at the receptor level. Where as dihydropyridines of the nifedipine type
(DHPs) are generally prepared by the well-known Hantzsch synthesis,357 aza analogues
of  DHPMs are readily available through the so called Biginelli dihydropyrimidine synthesis
.358 This  simple one-pot, acid catalyzed condensation  reaction of ethyl acetoacetate,
benzaldehyde and urea was first reported in 1893 by Pietro Biginelli.359-360 In the following
decades, the original cyclocondensation reaction has been extended widely to include
variations in all three components, allowing access to a large number of multifunctionalized
dihydropyrimidine derivatives.
DEFINITION OF MULTICOMPONENT REACTIONS (MCRs)
“In multicomponent reactions three or more reactants come togather in a single
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reaction vessel to form products that contain portions of all the components.361”
“MCRs converts more than two adducts directly in to their product by one-pot
reactions.362”
History and Types of Multicomponent  Reactions (MCRs)
First officially reported MCR was by Strecker  of α-amino nitrile in 1850.
1. Strecker A. Synthesis363
                  
R1 H
O
+
NH2
R2 + NaCN
R1 CN
NH
R2
2. Passerini reaction.364-365
              N+ C-R1 +
R2 R3
O
+ R4 COOH R1
NH
O
R4R3
R2
O
O
3. Guareschi-Thorpe condensation.366-367
                 
R1
R2
O
O +
O
NC
O
R3
+ NH3
N
H
R2
R1
CN
O
4. Mannich Reaction (1912).368-370
                 
R1
R2
O
R
NH
R H
O
H
N R2
O
R R1
R
H++ +
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4. Hantzsch Dihydropyridine synthesis (1882).371
            
CH3
CH3 O
O
+ NH3 +
CHO
N
H
CH3 CH3
COOCH3H3COOC
6. Robinsons synthesis of tropinone (1917).372
            
CHO
CHO
+CH3NH2
O
O
OH O
OH
NCH3 O+
7. Bucherer-Bergs Hydantoin synthesis (1929).373-374
                              + NH3 CO2+ + KCN
N
H
NH
O
O
R2 R1
R2
R1
O
MECHANISM
 Sweet and Fissekis Kappe375 was reexamined the mechanism in 1997 using
1H and 13C spectroscopy to support the argument that the key step in this sequence involves
the acid-catalyzed formation of an N-acyliminium ion intermediate of type (III) from the
aldehyde (I) and urea (II) precursors. Interception of the iminium ion (IV) by ethyl
acetoacetate, presumably through its enol tautomer, produces an open chain ureide which
subsequently cyclizes to hexahydropyrimidine(V). Acid-catalyzed elimination of water from
(VI)ultimately leads to the final DHPM product (VII).
            Dihydropyrimidinones...
150Studies on some compounds....
     
Ph CHO
NH2 NH2
O Ph
N
OH
H O
NH2 H
+
-H2O
Ph
N+
H
H O
NH2
-H+EtOOC
CH3 O
NH
N
H2
Ph
OCH3 O
EtOOC
-H2O
NH
N
H
OCH3
EtOOC
Ph
(III) (IV)
(V)(VII)
NH
N
H
O
CH3
EtOOC
Ph
OH-H2O
(I)
(VI)
(II)
+
Finally the original mechanistic proposal put forward by Folkers and Johnson376
in 1933 involving an aldehyde urea condensation product as key intermediate in the
Biginelli condensation is essentially correct. The first step in this mechanism evidently
involves the acid-catalyzed formation of an N-acyliminium ion precursor of type (IV)
from an aldehyde and urea component. In the case of amides and carbamates, this reaction
pathway is well-established,377 and at least one example exists for ureas.378 The second
step can be regarded as an addition of a π-nucleophile, i.e. the enol tautomer of
acetoacetate to the electrondeficient N-acyliminium species.  Additions of π-nucleophiles
to iminium species are very well-known and have proven to be valuable synthetic
transformations in target oriented synthesis.379 Importantly, several examples of this type
of reaction involving 1,3-dicarbonyl compounds and urea derived N-acyliminium ions
yielding dihydropyrimidines are reported in the literature,380 providing additional support
for this mechanism.
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THERAPEUTIC IMPORTANCE
Dihydropyrimidines show a very similar pharmacological profile to classical
dihydropyridine calcium channel modulators. Over the past few years several lead-
compounds were developed that are superior in potency and duration of antihypertensive
activity to classical DHP drugs. These inherently asymmetric DHPM derivatives are not
only very potent calcium channel modulators, but also have been studied extensively to
expand the existing structure activity relationships and to get further insight into molecular
interactions at the receptor level.
Dihydropyrimidines have attracted considerable attention as they appeared of
interest to possess wide range of therapeutic activities. Different activities are as under.
1. Anti-inflammatory381
2. Neuropeptide Y (NPY) antagonist382
3. Mitotic Kinesin inhibitor383
4. Metabotropic glutamate receptor antagonist384
5. Antiviral385
6. Anti-ichemic386
7. Blood platelet aggregation inhibitor387
8. Antitumor388
9. Coronary dilatory389
10. Cardiovascular activity390-391
11. Antihypertensive392
12. Calcium channel modulator393-394
Baldev Kumar et. al.395 have prepared some new oxo-pyrimidine derivatives
(VIII) and reported them as potent calcium channel blockers. Abd. El-Galil and M.
Abdulla396 have synthesized some fused steroidal oxo pyrimidine derivatives (IX) and
reported them as androgenic anabolic agent as well as antiinflammatory agent.
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N
H
NH
Ar
COOEt
MeO
NH
NH
OH
CH3
CH3
X
Cl
Recently, Vladimir N. Belov et. al.397 have documented enantioselective synthesis
of the novel antiinfective TAN-1057A via aminomethyl substituted dihydropyrimidinone
heterocycle (X). Rajni Garg et. al.398 suggest that the balance of hydrophobicity and a
volume dependent polarizability plays a key role in the inhibition of the viral protease by
these (XI) inhibitors.
                              
NN
O
OH
N
N
H
O NH NH2
O
N
CH3
R
Several potent, cell permeable 4-aryl-dihydropyrimidones have been identified
as inhibitors of fatty acid transporter FATP4. Christopher Blackburn et. al.399 described
that lipophilic ester substituents at the 5-position and substitution at the para-position
(optimal group -NO2 and CF3) of the 4-aryl group led to active compounds (XII,XIII)
( IX )( VIII)
( X ) ( XI )
X = O / S / NH
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N
H
NH
O
N
H
O
NO2
CH3
SEt
N
H
NH
O
O
O
NO2
CH3
Atwal K. S. et al.400 described that in order to explain the potent antihypertensive
activity of the modestly active  dihydropyrimidine calcium channel blocker (XIV), they
carried out drug metabolism studies in the rat and found (XIV) is metabolized to
compounds (XV-XVIII). Two of the metabolites, (XV) and (XVI) were found to be
responsible for the antihypertensive activity of compound (XIV). Potential metabolism
of (XV) into (XVI) in vivo. Structure-activity studies aimed at identifying additional
aryl-substituted analogues of (XIX) led to (XX,XXI,XXII) with comparable potential
in vivo, though these compounds were less potent than (XXI) in vitro.
The results demonstrate that the active R-(-)-enantiomer (XXIII) of (XIX) is
both more potent and longer acting than nifedipine as an antihypertensive agent in the
SHR. The in vivo potency and duration of (XXIII) is comparable to the long acting
dihydropyridine amlodipine.
   
N
N
H
NH
R
O
OCH3
PhOOC
NO2
(XV)      R = Me
(XVI)     R = H
(XVII)    R = CH2OH
(XVIII)   R = CHO
( XII) ( XIII)
(XIV)
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                 N
N
H
R3
OCH3
R1OOC  
R2
Dennis Russowsky et al.401 have reported manostrol was shown to be more active
than its oxo analogue, except for HT-29 cell line, suggesting the importance of the sulfur
atom for the antiproliferative activity. Manostrol and the thio derivatives displayed relevant
antiproliferative properties with 3,4-methylenedioxy derivative being approximately more
than 30 times potent against colon cencer (HT-29) cell line.
Murali T. G. et al.402 have synthesized several DHPM one analogues(XXIV)
among this (+)-(XXV) and  (+)-(XXVI) give excellent selectivity (>880-fold) over α1b
and α1d also showed good selectivity over several other recombinant human G-protein
coupled receptors. These compounds showed good functional potency in isolated human
prostate tissues, with Kbs comparable to their in vitro α1a binding data. In addition,
compound (+)-(XXV) also exhibited good uroselectivity (DBP Kb/ IUP Kb > 20-fold)
in the in vivo experiments in dogs.
             N
N
H
O
R2 N
O
R5
O
N
Ph
CN
R1
R3
R4
              R1         R2                      R3
(XX)  i-pr   2-NO2       CONH2
(XXI)  i-pr   3-Cl       CONH2
(XXII)  i-pr   2,3-oxadiazoyl    CONH2
(XXIII) i-pr   3-NO2       CONH2
(XIX)
     R1        R2        R3     R4      R5
(XXV)     CH3      NH2      F       H       F
(XXVI)   OCH3   OMe    H       F        F
(XXIV)
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Bharat L. et al.403 identify that compound (+)-(XXVII) was a lead compound
with a binding and functional profile comparable to that of (+)-(XXVI).
                       N
N
H
MeOOC
N
O
F
O
N
N
CH3
F
HH
CONH2
Andrew L. H. et al.404 studied compounds belong to the HEPT (XXVIII) chemical
series.405-409 HEPT or 1-[(2-Hydroxyethoxy)-methyl]-6-(phenylthio)thymine was one of
the earliest NNIs discovered but inhibits HIV-1 RT relatively weakly (IC50 ) 17 µM).410
MKC-442 (XXIX) or 6-Benzyl-1-(ethoxymethyl)- 5-isopropyluracil (I-EBU) is a very
potent inhibitor of HIV-1 RT (the IC50 being 2000-fold lower at 8 nM),
411-412 although
only three relatively minor alterations have been made to the HEPT structure. The
different spectrum of drug-resistance mutations between HEPT and MKC-442 parallels
the variation in potency. A single mutation (Tyr188His) renders the virus effectively
resistant to HEPT.413
                                     
NH
N O
O
CH3
O
S
OH
HETP
                   
NH
N O
O
O CH3
CH3
CH3
MKC-442
(XXVII)
   (XXVIII)   (XXIX)
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Flucytosine
(fluorocytosine)
Antifungal Agent.415
In vitro susceptibility of Candida
species isolated from cancer patients
against some antifungal agents.
Immunosuppressants
Oncolytic Drug
Non-nucleoside HIV-1 reverse tran-
scriptase inhibitor
Compound was active not only
against wild-type HIV-1 strains
(IC50 = 3 nM against IIIB and
NL4-3 HIV-1 strains) but also
showed nanomolar
Calcium Channel Blokers414
Company Name: Merck & Co.
TNK-6123
 NEW DRUG MOLECULES UNDER CLINICAL STUDY
Recently many new molecules which are under study from phase-I to phase-IV
clinical trials for different pharmacological action have shown that the basic characteris-
tic of morpholine to behave as hidden amine has attracted many medicinal chemists to
incorporate this feature in drug design. Some interesting compounds are as under.
            
N
H
NH
O CH3
O
CH3
NO2
            
N
NH
NH2
F
O
             N
NHNH
NH
N
Cl
Cl
Cl
Cl
O CH3
O
                
N
NH
S
CH3
CH3O
O
O
CH3
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 With an intention of preparing the compounds possessing better therapeutic activity,
we have undertaken the synthesis of dihydropyrimidinones which have been described
below.
 SECTION-I : SYNTHESIS AND BIOLOGICAL SCREENING OF 4-ARYL-
6-ISOPROPYL-5-[N-(3-NITROPHENYL) AMINO CARBO
NYL]-3,4-DIHYDROPYRIMIDINE-2-(1H)-ONES
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF  4-ARYL-6-ISOPROPYL-5-
[N-(3-NITROPHENYL) AMINO CARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H)-ONES
In the past years considerable evidence has been accumulated to demonstrate
the efficiency of pyrimidinones. it was considered worthwhile to synthesize 4-Aryl-6-
isopropyl-5-[N-(3-nitrophenyl)amino carbonyl]-3,4-dihydro pyrimidine-2(1H)-ones
type-(X) by the condensation of  4-Methyl-N-(3-nitrophenyl)-3-oxopentanamide nucleus,
urea and various type of aromatic aldehyde in presence of con.HCl as shown under.
          
O
CH3
CH3
O
NH
NO2
NH
N
H
CH3
CH3
O
NH
NO2
O
R
Aryl-CHO
NH2 NH2
O
2-3 dps HCl
The structure elucidation of synthesized compounds have been characterized by
using elemental analysis, IR spectra, 1H NMR spectroscopy and further supported by
Mass spectrometry.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg. The
biological activities of synthesized compounds were compared with standard drugs.
The details have been cited in (A), part-I, section-I(E), page no.047.
   Type (X)       R=Aryl
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NH2
O2N
+
O
O
H3CO
CH3
CH3
Toluene
O H
NH2
NH2 O
+
MethanolH+
NH
N
H
O
NH
O
CH3
CH3
NO2
Reflux
R
R
REACTION SCHEME
R = Aryl     Type-(X)
O
NH
O
CH3
CH3
NO2
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IR SPECTRAL STUDIES OF 4-(4-METHOXYPHENYL)-6-ISOPROPYL-5-[N-(3-
NITROPHENYL) AMINO CARBONYL]-3,4-DIHYDROPYRIMIDINE-2(1H)-
ONE
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1 (KBr disc.)
 Observed
Alkane C-H str. (asym.) 2977 2975-2950    189
-CH3 C-H str. (sym.) 2857 2880-2860      ,,
C-H i.p.def. (asym.) 1460 1470-1435      ,,
C-H o.o.p. def. (sym.) 1388 1390-1370      ,,
Aromatic C-H  str. 3087 3090-3030    190
C=C str. 1500 1540-1480      ,,
NO2 str. 1360 1385-1365       ,,
Pyrimidine C=C str. 1580 1580-1520      ,,
moity C-H str. 3025 3080-3030      ,,
C-H i.p. def. 1087 1125-1090      ,,
C=O str. 1687 1700-1725      ,,
NH str. 3285 3300-3200       ,,
Amide NH str. 3306 3410-3380     189
NH def. 1605 1635-1595      ,,
C=O str. 1677 1690-1660              ,,
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
NH
N
H
CH3
CH3
O
NH
NO2
O
O
CH3
H
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NMR SPECTRAL STUDIES OF 4-(4-METHOXYPHENYL)-6-ISOPROPYL-5-[N-
(3-NITROPHENYL) AMINO CARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H)-ONE
    Internal Standard : TMS; Solvent : DMSO : Instrument : BRUKER Spectrometer (400 MHz)
Signal   SignalPosition    Relative No     Multiplicity          Inference           J Value  No.          (δppm)           of protons                                                     In Hz
      1         1.54                  6H          doublet            CH-(CH3)2          -
    (a,b)         -
   2        3.68-3.81           1H              multiplet         -CH(c)                -
   3          3.79                 3H               singlet        -OCH3      -
   4        4.96-4.97           1H              doublet         Ar-H(f)      4
   5        6.83-6.85           2H              doublet        Ar-H(h-i)            8.64
   8         7.173                1H     singlet         -NH(d)     -
   9        7.24-7.26           2H    doublet        Ar-H(g-j)      8.6
  10        7.49-7.53           1H     triplet         Ar-H(n)      -
  11      7.71-7.72           1H                singlet        NH CO(k)      -
  12       7.90-7.93           1H              doublet         Ar-H(o)  8.1,1.48
  13       8.05-8.07           1H    doublet         Ar-H(m)  8.2,1.08
     14             8.60 1H            singlet   Ar-H(l)          -
     15        9.74-9.75 1H            doublet   -NH(e)         3.04
NH
N
H
CH3
CH3
O
NH
NO2
O
O
CH3
H
a
b
c
d
e
f
g
hi
j
k
lm
n
o
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EXPANDED AROMATIC REGION
MASS SPECTRAL STUDIES OF 4-(4-METHOXYPHENYL)-6-ISOPROPYL-5-
[N-(3-NITROPHENYL) AMINO CARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H)-ONE
NH
N
H
CH3
CH3
O
NH
NO2
O
O
CH3
H
m/z = 410
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MASS FRAGMENTATION
NH
N
H
CH3
CH3
O
NH
NO2
O
OCH3
m/z = 410
NH
N
H
CH3
CH3
O
NH
NO2
OCH3
m/z = 395NH
N
H
CH3
CH3
O
NH
NO2
O
m/z = 379
NO2
m/z = 121NH
N
H
CH3
CH3
O
NH
NO2
O
m/z = 303 m/z = 76
NH
N
H
O
NH2
O
OCH3
m/z = 245
N
H
NH
CH3
CH3 O
O
OCH3
m/z = 273
NH
O2N
O
m/z = 164
N
H
NH
O
O
CH3
m/z = 202
NH
N
H
CH3
CH3
O
H3CO
m/z = 106 m/z = 139
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 4-ARYL-6-ISOPROPYL-5-
[N-(3-NITROPHENYL) AMINO CARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H)-ONES
[A] Synthesis of 4-Methyl-N-(3-nitrophenyl)-3-oxopentanamide :
A mixture of Methyl-4-methyl-3-oxopentanoate 1.44 gm (0.01 mol) and 3-Nitro
aniline 1.38 gm (0.01 mol) was refluxed for 12 hrs in 30ml toluene. Methanol and toluene
mixture was collected by azeotropic distilation. In residual reaction mass toluene was
added toluene and washed with dilute HCl  then with water. The resulting organic layer
was kept over night at room temperature and filter it. Yield 71%, m.p.65 oC, Elemental
analysis calculated for C12H14N2O4 Requires : C-57.59%, H-5.64%, N-11.19%, Found
:  C-57.56%, H-5.61% , N-11.06 %.
[B] Synthesis of 4-(4-Methoxyphenyl)-6-isopropyl-5-[N-(3-nitrophenyl) amino
carbonyl]-3,4-dihydropyrimidine-2(1H)-one :
A mixture of urea 1.2 gm (0.02 mol), 4-Methoxy benzaldehyde 1.36g (0.01 mol)
and 4-Methyl-N-(3-nitrophenyl)-3-oxopentanamide 2.50gm (0.01 mol) in 25 ml of
methanol containing 2-3 drops of conc HCl was refluxed for 48hrs. The solution was
allowed to stand for 1hr at room temperature. Filter it and the product was crystallized
from methanol. Yield 41%, m.p.dec 250 oC, Elemental Anal.Cal. for C21H22N4O5 Requires
: C-61.45%, H-5.40%, N-13.65%, Found : C-61.46%, H-5.31%, N-13.59 %.
Similarly, other 4-Aryl-6-isopropyl-5-[N-(3-nitrophenyl) amino carbonyl]-3,4-
dihydropyrimidine-2(1H)-ones were prepared. The physical data are recorded in table
no.10.
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[C] Biological screening of 4-Aryl-6-isopropyl-5-[N-(3-nitrophenyl) amino
carbonyl]-3,4-dihydropyrimidine-2(1H)-ones :
Antimicrobial testing was carried out as described in (A), part-I, section-I(E),
page no.047. The zones of inhibition of test solutions are recorded in graphical chart
no.10.
Conclusion :
Antibacterial activity
The screening data indicated that among dihydropyrimidinone derivatives tested
compounds 10f, 10i, 10l showed greater degree of antibacterial activity against S.aureus.
However, the compounds 10c, 10d, 10i, 10j showed greater degree of antibacterial
activity against B.subtilis. The compounds 10a, 10c, 10g, 10k, 10l and 10d, 10h, 10j
showed greater degree of antibacterial activity against E.coli  and P. aeruginosa
respectively.
Antifungal activity
The screening data indicated that among dihydropyrimidinone derivatives tested
compounds 10c, 10d showed greater degree of antifungal activity against A.niger.
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    PART - II
STUDIES ON
DIHYDROPYRIMIDINETHIONES
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INTRODUCTION
Generally pyrimidine derivatives such as 1,4 dihydro thiopyrimidinone(I) In the
area of drug development, dihydroazines show great promise, particularly since the 4-
aryldihydropyridines exhibit powerful vasodilation activity via modifying the calcium ion
membrane channel.
416-420
 Additionally, dihydropyridines have been found to be actively
transport medication across biological membranes.
421
                                                    
NH
N
H
S
From the biochemical point of view, dihydroazines are of intense interest because
of presence of this group at the active site of the “hydrogen transferring coenzyme”
NADH (reduced nicotinamide adenine dinucleotide). This nucleotide is a central
participant in metabolic processes in living organisms, participates in the reduction of
various unsaturated functionalities.
MECHANISM
Despite the importance and current interest in dihydropyrimidines, the mecha-
nism of the classical three-component Biginelli condensation422 has not been elucidated
with certainly and remains disputed. The “carbonium ion mechanism” was proposed by
Sweet and Fissekis,423 who investigated the reaction in 1973 and suggested that an acid-
catalyzed aldol condensation is the first and limiting step of the Biginelli condensation. It
was proposed that under acid catalysis benzaldehyde and ethyl acet oacetate would
react in an aldol type fashion to produce the corresponding aldol (II), which dehydrates
(I)
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in the presence of acid to the resonance stabilized carbonium ion424-425(III). Interception
of cation (III) by urea or thiourea then produces ureides (IV), which ultimately cyclize
to the Biginelli products (V).
              
CH3 O
EtOOC
Ph-CHO
H
+
CH3 O
EtOOC
OH
Ph
-H2O
H
+
CH3 O
EtOOC C
H
Ph
+
NH2
NH2
S H
+
CH3
O
EtOOC
NH
Ph
SNH2
-H2O
NH
N
H
Ph
EtOOC
CH3 S
 ATWAL MODIFICATION
Apart from the traditional Biginelli condensation, there are only a few other
synthetic methods available that lead to DHPMs. Since most of these protocols lack the
experimental and conceptual simplicity of the Biginelli one-pot, one-step procedure,
none of these have any significance today or can complete with the original Biginelli
MCR approach. One noticeable exception is the so called “Atwal modification” of the
Biginelli reaction.426-428 Here, an enone  is first condensed with a suitable protected urea
or thiourea derivative under almost neutral condition.
(III)(II)
(IV)(V)
                Dihydropyrimidinethiones...
170Studies on some compounds....
           
R1O H
Ar
R2 O
O
+
NH2
NH2 S
NaHCO3
DMF
N
N
H
R2
R1O
O Ar
SH
THERAPEUTIC IMPORTANCE
Since 1967, variety of dihydropyridine derivatives have been synthesized in  search
of more potent vasodilating compounds with longer duration of action. Recently, Bayer
A.G.synthesized analogues of the dihydropyridine skeleton itself, for instance,
dihydropyran, dihydrothiopyran, dihydropyridazine and dihydropyrazine. Due to the
structural similarity between dihydro pyridine and dihydropyrimidine, we became
interested in the synthesis and pharmacological activities of pyrimidine class.429
Dihydropyrimidinethiones have attracted considerable attention as they appeared
of interest to possess wide range of therapeutic activities. Different activities shown by
these derivatives are as under.
1. Antilukemic.
430
2. α
1a
Adrenergic receptor antagonist.
431-432
3. Antitumor
433
4. Cardiovascular
434-435
5. Blood platelet aggregation inhibitor
436-437
6. Antiinflammatory
438-439
7. Anticarcinogenic
440
8. Calcium channel modulator
441-443
9. Autihypertensive
444-445
10. Vasodialative
446
11. anticarcinogenic activity447
12. analgesic 448
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Biginelli compound show a diverse range of biological activities. As early in 1930
simple derivative’s(VI) interest focused on the antiviral activity of  Biginelli compounds.449
                                                         NH
N
H
SCH3
H
O
O
CH3
Cl
NH
N
H
SCH3
Ph H
NH2
O
Pyrimidine-5-carboxamides derivatives of type (VII) were reported to possess
anticarcinogenic activity,450 antiinflammatory,451 analgesic452 and blood platelet ag-
gregation inhibitory activity.
453
George C. et al.454 prepared dihydropyrimidinethione (VIII) was equipotent to
nifedipine and amlodipine in vitro .  In the spontaneously hypertensive rat,
dihydropyrimidinethione (VIII) is both more potent and longer acting than nifedipine
and compares most favourably with the long acting dihydropyridine derivative amlodipine.
Dihydropyrimidinethione (VIII) has the potential advantage of being a single enantiomer.
                             N
N
H
CH3
PriCOO
S
COO
CF3
N
F
Salvatore B. et al.455 studied the stopped flow fluorometry indicates that monastrol
inhibits ADP release by forming an Eg5-ADP monastrol tertiory complex. Monastrol
(VII)(VI)
(VIII)
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reversibly inhibits the motility of human Eg5. Monastrol has no inhibitory effect on the
following members of the kinesin superfamily: MC5 (Drosophila melanogaster Ncd),
HK379 (H. sapiens conventional kinesin), DKH392 (D. melanogaster conventional
kinesin), BimC1-428 (Aspergillus nidulans BimC), Klp15 (Caenorhabditis elegans C-
terminal motor), or Nkin460GST (Neurospora crassa conventional kinesin).
Massey A. et al.456 report that growing human cells extensively incorporate the
thiopyrimidine nucleoside 4-thiothymidine (S4TdR) into their DNA. The incorporated
thiopyrimidine (S4T) can also undergo facile S-methylation to 4-thiomethylthymine
(S4meT). The rate of methylation of S4TdR in model substrates is similar to that for the
conversion of S6G to S6meG indicating that the DNA of cells grown in S4TdR will
contain significant levels of S4meT.
Twenty 5-alkyl-2-thiopyrimidine nucleosides were newly synthesized by Shigeta
S. et al.457 and examined for antiviral activities against herpes simplex virus (HSV),
varicella zoster virus (VZV) and human cytomegalovirus (HCMV). In this study, 2'-
deoxy-5-alkyl-2-thiocytidine (IX) analogues had lower 50% effective concentration
(EC50) values against HSV-1, and 2'-deoxy-5-alkyl-2-thiouridine (X) analogues showed
lower activity.
          
N
N
O
S
NH2
R
OH
OH
N
N
H
O
S
O
R
OH
OH
Various 2-thiopyrimidine derivatives have been synthesized by Sondhi  S.M. et
al.458 One of the compounds, Thiazolo[3,2-c]pyrimidine-5-thione derivatives (XI) showed
good antiinflammatory (37.4% at 100mg/kg p.o.) and analgesic activity (75% at 100mg/
kg p.o.). 7-(1-Mercapto-3,3,4a-trimethyl-4,4a,5,9b-tetrahydro-3H-pyrido[4,3-b]indol-
(IX) (X)
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7-yl)-3,3,4a-trimethyl-3,4,4a,5-tetrahydro-benzo[4,5]imidazo[1,2-c]pyrimidine-1-thiol
(XII) showed moderate activity against CDK-1 (IC(50)=5muM). The other compounds
showed moderate antiinflammatory (5-20%), analgesic (25-75%) and protein kinase
(CDK-5, GSK-3) inhibitory activities (IC(50)>10muM).
        
NNH
SCH3
CH3
S
CH3
NN
NH
NH
N
CH3
CH3
CH3
SH
CH3
CH3CH3
SH
With an intention of preparing the compounds possessing better therapeutic
activity, we have undertaken the synthesis of dihydropyrimidinethiones which have been
described in following section.
SECTION-I :  4-ARYL-6-ISOPROPYL-5-[N-(3-NITROPHENYL) AMINO
  CARBONYL]-3,4-DIHYDROPYRIMIDINE-2(1H)-THIONES
    (XI)                                            (XII)
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 4-ARYL-6-ISOPROPYL-5-[N-
(m-NITRO PHENYL)AMINO CARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H)-THIONES
Compounds containing pyrimidine ring are widely distributed in nature. Many of
these derivatives are reported to possess different biological activities. In view of these
report, we have synthesized  4-Aryl-6-isopropyl-5-[N-(3-nitrophenyl) amino carbonyl]-
3,4-dihydro pyrimidine-2(1H)-thiones type-(XI) by the condensation of 2-Arylidene-
4-methyl-N-(3-nitrophenyl)-3-oxopentanamide with thiourea in presence of potassium
bicarbonate.
                                          
NH
N
H
CH3
CH3
O
NH
NO2
S
R
The structure elucidation of synthesized compounds have been characterized by
using elemental analysis, IR spectra, 1H NMR spectroscopy and further supported by
Mass spectrometry.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The
biological activities of synthesized compounds were compared with standard drugs.
The details have been cited in (A), part-I, section-I(E), page no.047.
 Type-(XI)                 R=Aryl
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CH3
CH3
O
OMe
O
NH2
NO2
+
CH3
CH3
O
O
NH
O2N
NH
N
H
CH3
CH3
O
NH
S
R
NO2
O
R
+
Toluene
CH3
CH3
O
O
NH
R
O2N
NH2
S
NH2
Toluene
DMSO
KHCO3
morpholine/acetic acid
REACTION SCHEME
Type-(XI)                        R =Aryl     
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IR SPECTRAL STUDIES OF  4-(2-CHLOROPHENYL)-6-ISOPROPYL-5-[N-(3-
NITROPHENYL)AMINO CARBONYL]-3,4-DIHYDROPYRIMIDINE-2(1H)-
THIONE
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1 (KBr disc.)
 Observed
  Alkane C-H str. (asym.) 2922 2975-2950    189
  -CH3 C-H str. (sym.) 2860 2880-2860      ,,
C-H i.p.def. (asym.) 1435 1470-1435      ,,
C-H o.o.p. def. (sym.) 1390 1390-1370      ,,
  Aromatic C-H  str. 3091 3090-3030    190
C=C str. 1531 1540-1480      ,,
C-H o.o.p.(def) 821  832-802      ,,
NO2 str. 1346 1385-1365       ,,
  Pyrimidine C-H i.p. def. 1120 1125-1090      ,,
NH str. 3255 3300-3200       ”
C=S str. 1207 1270-1190       ”
   Amide NH str. 3350 3410-3380     189
NH def. 1616 1635-1595      ,,
C=O str. 1666 1690-1660             ,,
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
NH
N
H
CH3
CH3
O
NH
NO2
S
H
Cl
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NMR SPECTRAL STUDIES OF  4-(2-CHLOROPHENYL)-6-ISOPROPYL-5-[N-
(3-NITROPHENYL) AMINO CARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H)-THIONE
Signal    SignalPosition    Relative No      Multiplicity          Inference           J Value  No.         (δppm)             of protons                                                      In Hz
      1           1.49                  6H             doublet          -CH(CH3)2
      (a,b) -
   2           3.89                  1H                singlet          -CH(c) -
   3        5.55-5.56             1H               doublet           Ar-H(f)      4.16
   4        7.11-7.13             1H               doublet           Ar-H(j)           5.64,3.4
   5        7.25-7.27             2H       doublet           Ar-H(i-h)        5.98,3.4
   6        7.36-7.38             1H       doublet           Ar-H(g) -
   7        7.49-7.54             1H        triplet           Ar-H(n) -
   8        7.93-7.95             1H               doublet           Ar-H(o)   8.08 ,1.6
   9       8.12-8.15              1H        doublet           Ar-H(m)   8.12 ,1.2
     10              8.59    1H               singlet     Ar-H(l) -
     11            8.60    1H   singlet   -NH CO(k) -
     12        8.78-8.79    1H               doublet      -NH(e)        4.36
     13            9.22    1H    singlet      -NH(d) -
Internal Standard : TMS; Solvent : DMSO : Instrument : BRUKER Spectrometer (400 MHz)
NH
N
H
CH3
CH3
O
NH
NO2
S
H
Cl
a
b
c
d
e
f
g
h
i
j
k
lm
n
o
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EXPANDED AROMATIC REGION
MAAS SPECTRAL STUDIES OF    4-(2-CHLOROPHENYL)-6-ISOPROPYL-5-
[N-(3-NITROPHENYL) AMINO CARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H)-THIONE
NH
N
H
CH3
CH3
O
NH
NO2
S
H
Cl
m/z = 430
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MASS FRAGMENTATION
NH
N
H
CH3
CH3
O
NH
NO2
S
Cl
m/z = 430
NH
N
H
O
NH
NO2
S
Cl
m/z = 387
NH
N
H
CH3
CH3
O
NH
NO2
S
m/z = 396
NH
N
H
CH3
CH3
O
NH
NO2
S
m/z = 319
Cl
m/z = 111
NH
N
H
CH3
CH3
S
m/z = 230
NH2
NO2
m/z = 136
NH
N
H
CH3
CH3
S
m/z = 153 m/z = 77
NO2
NH
N
H
S
m/z = 111m/z = 122
                Dihydropyrimidinethiones...
180Studies on some compounds....
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 4-ARYL-6-ISOPROPYL-5-
[N-(3-NITROPHENYL) AMINO CARBONYL]-3,4-DIHYDROPYRIMIDINE-
2(1H)-THIONES
[A] Synthesis of 4-Methyl-N-(3-nitrophenyl)-3-oxopentanamide :
See(B), part-I, section-I (A), page no.164.
[B] Synthesis of 2-(2-Chlorobenzylidene)-4-methyl-N-(3-nitrophenyl)-3-
oxopentanamide :
To the mixture of 2-Chloro benzaldehyde 1.40gm (0.01mol) and 4-Methyl-N-
(3-nitrophenyl)-3-oxopentanamide 2.50gm (0.01mol), morpholine, acetic acid and
toluene were added and refluxed for 22 hrs with continuous removal of water by dean
and stark apratus. After completion of the reaction, cooled it at room temperature, filtered
the material and washed with toluene. Make a slurry of the material into the solution of
sodium meta bisulphite and remove excess aryl aldehyde.
Similarly, other  2-(2-Arylidene)-4-methyl-N-(3-nitrophenyl)-3-oxopentanamide
were prepared.
[C] Synthesis of 4-(2-Chlorophenyl)-6-isopropyl-5-[N-(3-nitrophenyl) amino
carbonyl]-3,4-dihydropyrimidine-2(1H)-thione :
To the mixture of 2-(2-Chlorobenzylidene)-4-methyl-N-(3-nitrophenyl)-3-
oxopentanamide 3.72gm (0.01mol) and thiourea 0.76gm (0.01mol) in DMSO,  potassium
bicarbonate was added and the mixture was stirred at 45-55 oC temperature for 20 hrs.
After completion of the reaction, cool down the reaction mixture at room temperature.
Slowly pour the reaction mixture  into a  mixture of crushed ice, dil. HCl and  toluene.
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Stir it for 1 hr then separate water layer and adjust pH 9-10 using liq NH3. Filter the
material and wash it with water. Recrystallized from isopropyl alcohol. Yield 56%,
m.p.dec 250oC ,Elemental analysis calculated for C20H19ClN4O3S Requires : C-55.75%,
H-4.44%, N-13.00%. Found : C-55.73%, H-4.45%, N-13.11%.
Similarly, other 4-Aryl-6-isopropyl-5-[N-(3-nitrophenyl) amino carbonyl]-3,4-
dihydropyrimidine-2(1H)-thiones were prepared. The physical data are recorded in table
no.11.
[D] Biological screening of 4-Aryl-6-isopropyl-5-[N-(3-nitrophenyl) amino
carbonyl]-3,4-dihydropyrimidine-2(1H)-thiones :
Antimicrobial testing was carried out as described in (A), part-I, section-I(E),
page no.47. The zones of inhibition of test solutions are recorded in graphical chart
no.11.
Conclusion :
Antibacterial activity
The screening data indicated that among dihydropyrimidinethione derivatives tested
compounds 11b, 11f, 11l showed greater degree of antibacterial activity against S.aureus.
However, the compounds 11k showed greater degree of antibacterial activity against
B.subtilis. The compounds 11c, 11e, 11g, 11l and 11h, 11j showed greater degree of
antibacterial activity against E.coli  and P. aeruginosa respectively.
Antifungal activity
The screening data indicated that among dihydropyrimidinethione derivatives tested
compounds 11d, 11j showed greater degree of antifungal activity against A.niger.
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STUDIES ON
1,4-DIHYDROPYRIDINES
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INTRODUCTION
In substituted 1,4-dihydro pyridine(I) either imino (NH) or substituted nitrogen
atom is present at one position and hydrogen atom at four position of the six member
hetrocyclic ring which can be represented as under.
                                         
N
R1
R6
R5
R4
R3
R2
H
Dihydropyridines are the largest and the most studied class of drugs having cal-
cium channel blockers459 activity. In addition to their proven clinical utilities in cardio-
vascular medicine, dihydropyridines are employed extensively as  biological tools for
the study of voltage-activated calcium channel.460
From  study of DHP compounds, it is found that both the ester groups
present at 3 and 5 position play an important role in cardiovascular activity, removal of
these groups may led to reduction of the activity.461  This conclusion has open up
new  scope for structural modifications at these positions. Very wide range of litera-
ture regarding the structure, synthesis, stereochemistry and hydrogen transfer mecha-
nism of dihydropyridine is available.462-467 As it is very pertinent to work on these
issues, more than 10,000 articles,  publications & patents are published in the literature
on the  1,4-DHPs.
Lot’s of 1,4-dihydropyridine derivatives have been synthesized and developed
as calcium channel antagonists which inhibit smooth and cardiac muscle contractions by
blocking the influx of Ca+2 through calcium channels and antihypertensive action.468-170
(I)
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SYNTHETIC ASPECT
Different methods for the synthesis of 1,4-dihydropyridine are as follows.
1. By the knoevenagel condensation of benzaldehyde with acetoaceticester in pres
ence of β-alanine as catalyst and subsequent cyclocondensation of the resulting
benzylidene with 3-amino crotonate.471
2. By the regio and chemoselective addition of  Ph2Cu(CN)Li2 to substituted N-
alkyl pyridinium salts followed by acylation of the intermediate.472
3. By the condensation of 1,3-diketones, alkyl or aryl aldehydes with aqueous ammo
nium hydroxide in the presence of piperidine or piperidyl acetate or potassium
acetate or potassium carbonate or glacial acetic acid.473-4775
4. By the condensation of two moles of thiobarbituric acid, aromatic amines and
aromatic aldehydes.476-477
5. By the condensation of aromatic or aliphatic aldehydes with acetoacetic ester
and aromatic or aliphatic amine in presence of pyridine.478-481
6. By the condensation of arylidene with 3-aminocrotonate.482
           
CH3
H3CO
O
O
R
+
CH3
OMe
O
NH2
COOMe
CH3N
H
R
CH3
MeOOC
-H2O
7. By the condensation of aliphatic or aromatic aldehydes with various 1,3-dike
tones in presence of ammonia or ammonium carbonate.483-485
8. By the condensation of α,β-unsaturated ketones with malononitrile and cyanoac
etamide.486
9.      By the condensation of o-nitrobenzaldehyde, β-amino butaricacid and methyl
propionate in glacial acetic acid.487
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10. Shengkao Ko et al488 have synthesized 1,4-dihydropyridine by one pot reaction,
catalyzed by iodine at room temperature.
                 
O
O
+
CH3O
O
OC2H5
NH4OAc
I2
r.t.
N
H
OC2H5
CH3
OO ArO
Ar
11. By the condensation of aliphatic or aromatic aldehydes with 3-amino croton
ate and 1,3-diketone.489-496
               
R2 O
O
R
R1
+
CH3
OMe
O
NH2
COOMe
CH3N
H
R
R2
R1
-H2O
MECHANISM
The first dihydropyridine was in fact isolated back in 1882 as a stable intermediate
from this method.497 In its simplest form of the synthesis involves heating an aldehyde,
1,3-diketone and ammonia.
The reaction almost certainly involves aldol condensation to form the benzylidene
derivative as the first step. Conjugated addition of a second mole of 1,3-diketone would
then afford the 1,5-diketone. Reaction of the carbonyl group with ammonia will lead to
the formation of the dihydropyridine ring to give many drug molecules that has been
used extensively for treatment of angina498 and hypertension.499
R1,R2 = Aryl/Alkyl
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THERAPEUTIC INTEREST
The research on 1,4-dihydropyridine system is of current interest due to their
valuable activities as calcium channel antagonist, vasodilator, cardiovascular, etc. Beside
the currently established drugs Nifedipine500-501 Nicardipine502-503 many dihydropyridine de-
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tion commercial products,505-506 such as Nimodipine,507-508 Nisodipine,509 Nitrendipine,510
Amlodopine,511 Felodipine,512 Isradipine,513 Manidipine514 and Nilvadipine.515 Some of
their compounds are characterized by longer bioactivity of greater tissue selectivity. 1,4-
Dihydropyridine derivatives are associated with diverse biological activities viz.
1. Antiarythmic516
2. Antiinflammatory517
3. Antiallergic518
4. Antiulcer519
5. Vasodilator520
6. Enzymetic521-522
7. Antitubercular agents523
Cozzi et al.524 studied anticancer activity especially as an aromatase inhibitory
activity of dicyano and cyanoester derivatives of 1,4-DHP containing an imidazol-1-yl
or 1,2,4-triazol-1-yl ring (II) at C4 position of phenyl ring. Aromatase inhibitory activity
recorded in vitro near to 10-9M concentration.
                                
N
N
X
N
R2
CH3 CH3
R1NC
Kilcigil and coworkers525 synthesized new type of symmetrical dicarbamoyl 1,4-
dihydropyridines with some flavone derivatives at C4 position of DHP ring by react-
ing 6-formylflavones with acetoacetanilide. Their aim was to investigate the calcium
 R1 = CN, R2 = H, CH3
  X = CH
(II)
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antagonistic activity on this skeletal changes. Few newly synthesized compounds showed
good calcium antagonistic activity with nifedipine as the reference compound.
                                
N
H
NHNH
OO
CH3 CH3
O
O
Shah et al526 have synthesized many symmetrical DHPs with 3,5-diacetyl-1,4-
dihydropyridine and they studied the interaction between ampicillin, erythromycin and
synthesized molecules (IV) on different strains of E.coli.
They also studied and investigated the cytotoxic and mdr reversal activities against
the mouse lymphoma cells transected with mdr21.
Moreover the same author group527 synthesized many compounds with dibenzoyl
functionality and concluded that new series of mdr modulators can be derived from the
BzDHPs  and they found that mdr reversal was dependant on the nature of substituents
and their position at the C4 phenyl ring of BzDHPs.  Among them one compound has
shown high mdr modulating potency and the tumor specific cytotoxicity including a new
drug candidate for mdr cancer therapy.
(III)
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N
H
CH3CH3
COCH3H3COC
R
N
H
CH3CH3
COCH3H3COC
NO2
N
H
CH3CH3
COPhPhOC
NO2
Shah et al528 was pioneer in the investigation of the 3,5-diacetyl and 3,5-dibenzoyl-
1,4-DHPs (DP1-11) (V)on vascular function in vitro, by comparing their mechanical
and electrophysiological actions  respectively, to quantify their multidrug resistance (mdr)
reversing activity in L5178 Y mouse t-lymphoma cells transfacted with mdr1 gene and
they suggest that DP7 may represent a lead compound for the design of novel, safe and
potent MDR chemosensitizers needed for the chemotherapy of the cancer and other
diseases.
                                           
N
H
O O
CH3 CH3
R
R= 3-CF3, 3-NO2, 3-Cl, 2-NO2, 2-Cl, 3-Br, 3-OCH3, 3-OPh etc...
(IV)
R= 3-CF3, 3-NO2, 3-Cl, 2-NO2,
2-Cl, 3-Br, 3-OCH3, 3-OPh etc... (V)
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STRUCTURAL REQUIREMENT FOR ANTITUBERCULAR ACTIVITY  IN
1,4-DHPS FROM QSAR STUDY
                                   
N
H
CH3 CH3
NHNH
O O
R
R'R'
Many derivatives of the type (VI) were screened for their antitubercular activity
against M.tuberculosis H37 RV out of which, among them some molecules showed >90%
inhibition comparable to rifampicin.
The QSAR study of all these derivatives indicates that the presence of bulkier
substituents in the phenyl ring at C4 position of the dihydropyridines positively contrib-
utes for the antitubercular activity529. The electronic influence of the substitutions at the
carbamoyl phenyl ring present at 3 and 5 position of dihydropyridine are important for
antitubercular activity. The presence of the electron withdrawing  group(EWG) at meta
and para position increases activity. This electronic influence the enzymatic hydrolysis
of the amide bond present at 3 and 5 position of substituted dihydropyridines to corre-
sponding acids inside the M.tuberculosis.
SECTION - I  : SYNTHESIS AND BIOLOGICAL SCREENING OF 4-ARYL-
    2,6-DIISOPROPYL-3,5-BIS[N-(3-NITRO PHENYL)AMINO
    CARBONYL]-1,4-DIHYDRO PYRIDINES
R= Cl, NO2, Br, OC6H5 etc..
R’= NO2, OCH3, Cl etc.. (VI)
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 4-ARYL-2,6-DIISOPROPYL-
3 ,5 -BIS[N - (3 -NITROPHENYL)AMINOCARBONYL]-1 ,4 -DIHYDRO
PYRIDINES
 In view of getting better therapeutic agent and considering the association of
various biological activity with pyrimidine nuclei, the synthesis of 4-Aryl-2,6-diisopropyl-
3,5-bis[N-(3-nitrophenyl)aminocarbonyl]-1,4-dihydro pyridines of type-(XII) have been
carried out by the condensation of 4-Methyl-N-(3-nitrophenyl)-3-oxopentanamide,
ammonical methanol and various type of aromatic aldehydes.
                              N
CH3
CH3
O
NH
CH3
CH3
O
NH
NO2NO2
R
The structure elucidation of synthesized compounds has been characterized by
using elemental analysis, IR spectra, 1H NMR spectroscopy and further supported by
Mass spectrometry.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg. The
biological activities of synthesized compounds were compared with standard drugs.
The details have been cited in (A), part-I, section-I(E), page no.047.
Type-(XII)                            R=Aryl
                                 Sym dihydropyridines...
193Studies on some compounds....
                                
NH2
O2N
+
O
O
H3CO
CH3
CH3
Toluene
O H
Ammonical methanol
Reflux
R
REACTION SCHEME
Type - (XII)                                R = Aryl     
O
NH
O
CH3
CH3
NO2
N
CH3
CH3
O
NH
CH3
CH3
O
NH
NO2NO2
R
                                 Sym dihydropyridines...
194Studies on some compounds....
IR SPECTRAL STUDIES OF 4-(4-FLUOROPHENYL)-2,6-DIISOPROPYL-3,5-
BIS[N-(3-NITROPHENYL)AMINOCARBONYL]-1,4-DIHYDROPYRIDINE
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1 (KBr disc.)
Alkane C-H str. (asym.) 2968 2975-2950     189
-CH3 C-H str. (sym.) 2872 2880-2860       ,,
C-H i.p.def. (asym.) 1421 1470-1435       ,,
C-H o.o.p. def. (sym.) 1350 1390-1370       ,,
Aromatic C-H  str. 3084 3090-3030     190
C=C str. 1487 1540-1480       ,,
C-H i.p.(def) 1242 1269-1247       ,,
C-H o.o.p.(def)  804   832-802       ,,
NO2 str. 1350 1385-1365        ,,
Pyridine C=C str. 1530 1580-1520       ,,
moity N-H str. 3448 3440-3400       ,,
C-N str. 1242 1300-1200        ,,
Amide NH str. 3292 3410-3380      189
NH def. 1608 1635-1595       ,,
C=O str. 1645 1690-1660       ,,
     Frequency in cm-1
Observed         Reported
  Type  Ref
 Vibration
    Mode
N
H
CH3
CH3
O
NH
F
CH3
CH3
O
NH
NO2NO2
                                 Sym dihydropyridines...
195Studies on some compounds....
NMR SPECTRAL STUDIES OF 4-(4-FLUOROPHENYL)-2,6-DIISOPROPYL-
3 ,5 -BIS[N - (3 -NITROPHENYL)AMINOCARBONYL]-1 ,4 -DIHYDRO
PYRIDINE
Signal  SignalPosition    Relative No    Multiplicity        Inference              J Value
  No.         (δppm)           of protons                                                    In Hz
      1        1.18-1.30          12H           doublet           -CH(CH3)2          7
  (a-a’,b-b’)
   2        3.64-3.71           2H               multiplate         -CH(c-c’) -
   3            4.96               1H                 singlet           Ar-H(e) -
   4            6.24               1H                 singlet           -NH(d) -
   5        6.91-6.96           2H       triplet          Ar-H(n-k)           11
   6        7.20-7.24           2H      doublet          Ar-H(l-m)      8.5
   7        7.45-7.49           2H       triplet          Ar-H(h-h’) -
   8        7.85-7.88           2H                doublet          Ar-H(g-g’)  8.1 ,1.68
   9       7.91-7.93           2H      doublet          Ar-H(i-i’)  8.24,1.08
     10          8.62-8.63             2H              triplet    Ar-H(j-j’) -
     11            9.70             2H  singlet   -NH CO(f-f’) -
Internal Standard : TMS; Solvent : DMSO: Instrument : BRUKER  Spectrometer (400 MHz)
N
H
CH3
CH3
O
NH
F
CH3
CH3
O
NH
NO2NO2
a
b c
d
ef
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h
i j k
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n
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EXPANDED AROMATIC REGION
MASS SPECTRAL STUDIES OF 4-(4-FLUOROPHENYL)-2,6-DIISOPROPYL-
3 ,5 -BIS[N - (3 -NITROPHENYL)AMINOCARBONYL]-1 ,4 -DIHYDRO
PYRIDINE
N
CH3
CH3
O
NH
F
CH3
CH3
O
NH
NO2NO2
m/z = 585
                                 Sym dihydropyridines...
197Studies on some compounds....
MASS FRAGMENTATION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 4-ARYL-2,6-DIISOPROPYL-
3 ,5 -BIS[N - (3 -NITROPHENYL)AMINOCARBONYL]-1 ,4 -DIHYDRO
PYRIDINES
[A] Synthesis of 4-Methyl-N-(3-nitrophenyl)-3-oxopentanamide :
See(B), part-I, section-I (A), page no.164.
[B] Synthesis of 4-(4-Fluorophenyl)-2,6-diisopropyl-3,5-bis[N-(3-nitrophenyl)
aminocarbonyl]-1,4-dihydropyridine :
A mixture of 4-Methyl-N-(3-nitrophenyl)-3-oxopentanamide 2.50 gm (0.01 mol)
and 4-Fluoro benzaldehyde 1.24gm (0.01mol) in ammonical methanol was refluxed for
8hrs. Cooled it at room temprature and kept over night. The resulting solid mass separated
out was filtered and washed with methanol. Recrystallized the product from DMF and
methanol. Yield 72%, m.p.dec.205oC, Elemental analysis calculated for C31H28FN5O6
Requires : C-63.58%, H-4.82%, N-11.96%, Found : C-63.56, H-4.88, N-11.99%.
Similarly, other 4-Aryl-2,6-diisopropyl-3,5-bis[N-(3-nitrophenyl)amino
carbonyl]-1,4-dihydropyridines. The physical data are recorded in table no.12.
[C] Biological screening of 4-Aryl-2,6-diisopropyl-3,5-bis[N-(3-nitrophenyl)
aminocarbonyl]-1,4-dihydropyridines :
Antimicrobial testing was carried out as described in (A), part-I, section-I(E),
page no.47. The zones of inhibition of test solutions are recorded in graphical chart
no.12.
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Conclusion :
Antibacterial activity
The screening data indicated that among dihydropyridine derivatives tested
compounds 12b, 12e, 12f, 12l showed greater degree of antibacterial activity against
S.aureus. However, the compounds 12l showed greater degree of antibacterial activity
against B.subtilis. The compounds 12e, 12g, 12h and 12b showed greater degree of
antibacterial activity against E.coli  and P. aeruginosa respectively.
Antifungal activity
The screening data indicated that among dihydropyridine derivatives tested
compounds 12c, 12d, 12g, 12k showed greater degree of antifungal activity against
A.niger.
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